Nuclear imaging for immune cell tracking in vivo – Comparison of various cell labeling methods and their application

Łukasz Kiraga, Paulina Kucharzewska, Stephen Paisey, Łukasz Cheda, Anita Domańska, Zbigniew Rogulski, Tomasz P. Rygiel, Alberto Boffi, Magdalena Król

Abstract

There is currently great interest in the development of cell-based therapies, particularly those focused on the idea of exploiting systemically administered immune cells for therapeutic purposes in cancer (e.g., CAR-T and CAR-NK cells). The ability to monitor the fate of cells in vivo after administration is vital for the assessment of therapeutic outcomes of immune cell-based therapies both in preclinical research and clinical practice. In this context, imaging techniques, which allow for noninvasive and real-time monitoring of the distribution and long-term viability of the adoptively transferred immune cells in the tissue of interest, are of paramount importance. Among clinically relevant in vivo imaging modalities, the nuclear imaging techniques, comprising planar scintigraphy, SPECT, and PET, are considered to be of pivotal importance to in vivo cell tracking and designing optimal treatment strategies for cell-based therapies. This review paper focuses on nuclear imaging and its role in the evaluation of immune cell-based therapies’ effectiveness – tracking cells and their ability to home to the target tissue. We compare different types of radiotracers, outline various ways of immune cell labeling, and provide the latest examples for the use of nuclear imaging techniques both in preclinical studies and clinical settings.

Keywords:
Nuclear imaging, SPECT, PET, Radiotracers, Immune cell tracking, Cell labeling

1. Introduction
2. Nuclear imaging overview
   2.1. Nuclear imaging modalities
   2.2. Radiotopes for nuclear imaging
3. Labeling strategies of immune cells for tracking in vivo with nuclear imaging
   3.1. Direct cell labeling
      3.1.1. Tracking of directly labeled immune cells with planar gamma-scintigraphy and SPECT imaging
      3.1.2. Tracking of directly labeled immune cells with PET imaging
      3.1.3. Tracking of immune cells with radiolabeled antibodies – SPECT and PET
   3.2. Indirect cell labeling
      3.2.1. Tracking of indirectly labeled immune cells with SPECT imaging
      3.2.2. Tracking of indirectly labeled immune cells with PET imaging
4. Cell tracking in clinical practice
5. Summary
1. Introduction

Adoptive transfer of immune cells for inflammatory and neoplastic diseases is the subject of intense clinical research. So far, methods involving the administration of different types of autologous lymphocytes have shown great potential to treat different diseases. Such a therapeutic approach is especially promising in the treatment of cancer [1,2] as well as other disease conditions, including allergies, infections, and inflammation [3–5]. The type of immune cells to be selected for the adoptive therapy depends on the treated pathology. Among diverse immune cells tested so far, T cytotoxic lymphocytes (CTLs), T regulatory lymphocytes (Tregs), natural killer (NK) cells, monocytes, macrophages, eosinophils, neutrophils, and dendritic cells (DCs) all appear to play an emerging role.

Inarguably, the efficacy of cell-based therapies depends on the successful targeting of pathological lesions by the adoptively transferred cells. When considering novel approaches to this kind of treatment, the targeting efficiency of selected cells to the pathological lesion should be evaluated first. In this context, molecular imaging techniques, which enable noninvasive and real-time monitoring of the cell distribution in the tissues of interest, take center stage, as they provide key information on the long-term survival of the adoptively transferred immune cells. Among clinically relevant in vivo imaging modalities, the nuclear imaging techniques, comprising planar scintigraphy, SPECT, and PET, are considered to be of pivotal importance to in vivo cell-tracking as they can afford the design of optimal treatment strategies for cell-based therapies.

Tracking of immune cells with nuclear imaging has been used for a long time in routine medical practice for diagnostic purposes in infections and inflammation [5]. Immune cell labeling for cell tracking with nuclear imaging can be accomplished with direct or indirect methods. Direct methods involve the labeling of immune cells with radiotracers in vitro before cell transfer, whereas indirect labeling relies on the introduction of a reporter gene into immune cells to induce an additional function that makes the cells uniquely targetable by a specific radiotracer in vivo after cell transfer. In this Review, we provide the description of various nuclear imaging modalities in the context of live tracking of immune cells, outline immune cell labeling methods, and underline the latest examples for the use of nuclear imaging techniques both in preclinical and clinical research.

2. Nuclear imaging overview

Nuclear imaging is routinely employed in medical practice to assess disease severity and treatment effect. It involves oral, intravenous, or inhalation administration of small doses of a radiopharmaceutical (radiotracer), which consists of a short-lived gamma-emitting radionuclide conjugated to a chemical probe, capable of targeting the desired cellular or molecular process with high affinity and selectivity. The ionizing radiation thus emitted is then measured and imaged using an imaging device. The spatial resolution coupled to the capabilities of the probes to interact with specific cellular targets classify nuclear imaging among the molecular imaging techniques. Radioisotope-based imaging is commonly used for diagnostic purposes in cancer as well as in neurological, cardiovascular, gastrointestinal diseases, and cysts in kidneys [6–9]. In addition to diagnostic applications, nuclear imaging can also be selected to treat certain cancers such as non-Hodgkin lymphoma and thyroid-related tumors by radio-immunotherapy [10]. Nuclear imaging has become the most attractive and powerful modality for molecular imaging in personalized cancer therapy. Considering the type of image obtained, we can distinguish two groups of nuclear imaging techniques: planar (2D) gamma scintigraphy and spatial (3D) methods, including single-photon emission computed tomography (SPECT) and positron emission tomography (PET).

Nuclear imaging offers a range of important benefits in preclinical and clinical research, which lead to its routine use in many clinical applications. Primarily, nuclear imaging techniques are extremely sensitive to injected tracers compared to magnetic resonance imaging (MRI) and computed tomography (CT)-based techniques maintaining at least a similar level of sensitivity as optical imaging methods. Radiation detectors can detect picomolar concentrations of radiotracers. This sensitivity allows the use of subpharmacological quantities of radiotracers, avoiding the risk of biological side effects. Secondly, nuclear imaging is non-invasive and therefore can be applied in series to identify the longitudinal run of certain processes (e.g., reaction to the implemented therapy). Thirdly, thanks to suitable image analysis techniques, both PET and SPECT allow quantitative data to be obtained, such as the concentration of radiotracers in certain regions or volumes of interest (ROI/VOI). Fourthly, a great number and diversity of radiopharmaceuticals such as metabolites and their analogs, ligands for specific receptors, or antibodies are still being developed to provide an ever more accurate and relevant characterization of biological phenomena in situ [11–13]. However, nuclear imaging has its flaws. One of them is a moderate spatial resolution that ranges from ~2 mm to ~6 mm for PET or more for SPECT and is much worse than that of CT and MRI. Furthermore, nuclear imaging, by definition, is based on radioactive decay, and provides patients with low, but probably not insignificant, doses of radiation [14,15]. Finally, nuclear imaging delivers images with imprecise anatomical information, which may make their interpretation and analysis difficult. However, nowadays this limitation can be overcome by combining it with different imaging techniques, such as CT or MRI, which show anatomical structures in greater detail. Thanks to the widespread use of hybrid imaging methods such as SPECT/CT, PET/CT, and even PET/MRI, which are currently accessible at the clinical and preclinical level, it is feasible to obtain detailed functional and anatomical information during one study.

2.1. Nuclear imaging modalities

Planar gamma scintigraphy measures and images the location of the radiotracer in one 2D image. The signals from an array of photomultipliers in a gamma detector are transmitted to the position-coding matrix and reconstructed on an oscilloscope screen. In such a manner, the distribution and accumulation of the radiolabeled probe in the organism are visualized [16]. For dynamic imaging, multiple “frames” of images between 1 s (beginning) and 1 min
Comparison to PET and clinical applications of quantitative SPECT

Sensors usually have lower spatial resolution and sensitivity in comparison to PET, which only detects 511 keV gamma rays. The imaging is carried out by a gamma detector, which obtains a set of two-dimensional projection images at different angles. Typically, one, two, or three detectors or heads are slowly rotated around the patient’s body, while acquiring the information needed to reconstruct 3D images. Usually, clinical cameras have a resolution between 7 and 15 mm and preclinical devices between 0.8 and 1.5 mm. Usually, the SPECT tool is combined with CT and it applies a specific algorithm to reconstruct the projection data, to generate a spatial image of the administered radioisotope distribution. Pin-hole collimators at a distance of several centimeters from the detector are often used for imaging small animals as they enable magnification of the image on the detector achieving very high resolutions, even sub-millimeter: 0.25–0.6 mm [18], at the expense of a reduction in detector sensitivity. An important advantage of SPECT is the possibility that multiple radioisotopes can be imaged at the same time thanks to the ability to detect photons of different energies. Therefore, several different cell populations, each labeled with a different radioisotope, can be tracked during the same imaging procedure [19].

PET imaging records gamma photons generated during the annihilation of positrons (β⁺). The sources of positrons are the β⁻-decayed radioisotopes. Emitted positrons, after a free path of not more than a few millimeters, collide with electrons in body tissues, leading to the annihilation of the positron and the electron [20]. The annihilation event produces two photons, each of energy 511 keV, moving in opposite directions from each other (at an angle of 180°). The angle can be slightly different due to the result of kinetic motion (like Fermi motion). This has a significant impact on resolution, especially with large-diameter (distances between opposite detectors) scanners [21]. The photons are detectable by the use of a PET camera, which is composed of an array of crystal sensors usually in a ring configuration surrounding the sample or patient. The coincidence detection mechanism searches for pairs of photons detected within about a 10 ns coincidence window on opposing sections of the detector at different angles around the object, enabling the precise determination of the positron formation point. After reconstruction to localize the points where the annihilation occurred, the 3D visualization of the isotope distributed in the organism is possible. Importantly, PET acquisition time is shorter than in the case of SPECT, due to a combination of the static ring detector sampling all radial lines of response simultaneously, and the fact that sensitivity is increased as collimation is not required. This feature allows reliable dynamic imaging to be performed, which allows pharmacokinetic modeling of the radiotracer to calculate rates of uptake, binding affinities, and receptor densities in tissues. The spatial resolution, which is measured as total width at half maximum, is usually about 2–6 mm, while preclinical animal scanners reach a resolution of 0.3–2 mm [16].

According to the quantitative ability of imaging modalities, PET is considered as the most valuable technique in this regard. A very high level of signal quantification accuracy is required especially in the case of cell-tracking studies, therefore in this context PET seems to be the preferred tool [22]. However, although SPECT scanners usually have lower spatial resolution and sensitivity in comparison to PET and clinical applications of quantitative SPECT imaging are lacking due to the insufficient availability of accurately calibrated SPECT reconstructions, currently produced SPECT instruments often exhibit quantitative ability comparable to PET. Routine corrections for resolution recovery, photon attenuation and scattering, radioactive decay, cross-calibration, and instrumental dead time are applied to enable quantitative SPECT analyses [23,24]. Nevertheless, detailed quantitative studies are nowadays performed mainly by using PET. A schematic presentation of the SPECT and PET scanners and their imaging modalities is shown in Fig. 1. In Table 1, the schematic mechanisms of action and main differences between SPECT and PET imaging techniques are given. For a thorough comparison of SPECT and PET imaging, the interested reader is referred to the additional review articles [11,19,25].

The technique called “whole-body counter” also deserves mention, although it does not provide an image in the full sense of the word. In this method, high-sensitivity scintillation probes are moved along the patient’s body, generating a quantitative profile of radioactivity from certain regions. The counter is isolated from the background radiation, which results in high sensitivity in the detection of photons, making it possible to administer radiotracers at very low activity.

2.2. Radioisotopes for nuclear imaging

There are a number of conditions that need to be satisfied for a radioisotope to be suitable for in vivo imaging. The unbound radioisotope and its decay products, which are commonly different elements from the parent isotope, must not exhibit any toxicity at clinical doses. The satisfaction of this criterion is helpful in determining the extremely high sensitivity of nuclear imaging modalities, with just picomoles of radiotracer required for typical clinical doses. The radioisotope must also be capable of readily forming biologically active compounds or complexes that are soluble and chemically stable in biological conditions. In addition to these standard biochemical requirements for pharmaceutical agents, a radioisotope must also have favorable radioactivity properties. It must be possible to produce and isolate the radioisotope in high radiochemical purity with a high specific activity. The high radiochemical purity is important because any alternative radioisotopes present in the sample will cause spurious signals in the images and interfere with the interpretation of the images. The high specific activity is important because high levels of non-radioactive isotopes of the element can interfere with tracer synthesis and can lead to the inadvertent co-administration of non-radioactive versions of the tracer which are not detected by the scanner but act as ‘cold’ blocking agents hindering the uptake of the radiotracer. Also, the radioisotope must emit radiation that penetrates enough to leave the body to enable its external detection. These are most commonly single gamma rays in the case of planar gamma scintigraphy and SPECT imaging or the pair of 511-keV annihilation gamma rays emitted during positron (β⁺) decay employed in PET imaging. Ideally, non-penetrating radiation, i.e. particulate radiation, including electrons (apart from positrons relevant for PET) and β⁻ particles, should only be emitted in small amounts by imaging radionuclides. This is because particulate radiation does not leave the body and cannot be measured with external detectors, but will still contribute to the radiation dose experienced by the tissues. Importantly, the imaging radioisotope should have a radioactive half-life comparable with the biological half-life of the probe, allowing for the radiotracer to reach the tissue of interest while still preserving an optimal imaging signal. In this way, patients can be exposed to minimal radiation dose. Table 2 summarizes the relevant physical properties of single-photon and positron-emitting radionuclides commonly used in nuclear imaging.
The ideal radioisotope for planar gamma scintigraphy and SPECT should emit gamma and X rays with 100–200 keV energies at 100% abundance. Additionally, it should emit only marginal amounts of particulate radiation or high energy gamma and X rays with energies above several hundred keV, which are not efficiently collimated and detected. By giving off only a 140-keV gamma-ray and few particulate radiations, technetium-99m ($^{99m}\text{Tc}$) is an almost ideal radioisotope for planar gamma scintigraphy and SPECT imaging. The latest devices allow obtaining full-width at half-maximum (FWHM) value of less than 0.4 mm for $^{99m}\text{Tc}$ in the center of Field of View (FOV) [18,26]. Unlike $^{99m}\text{Tc}$, iodine-131 ($^{131}\text{I}$), for example, emits high-energy (364 keV) gamma rays and high amounts of $\beta^-$ particles, allowing the compound to exhibit both diagnostic and therapeutic properties. The spatial resolution of SPECT images is influenced by many factors including the energy of photons emitted by the radioisotope, the number and shape of pinholes in collimators, and the type of detector. The use of radionuclides with energy values of gamma rays significantly different from technetium clearly affects the sensitivity of the device and parameters of the acquired image [26]. However, modern devices using collimators of greater thickness and varied geometry allow the use of isotopes with the higher energy of emitted gamma radiation, even exceeding the values used in PET technique. Thus, the proper selection of collimators makes it possible to keep the FWHM value at a relatively constant level when using radioisotopes emitting energies in the range 100–500 keV [27–29]. The relationship is not obvious when considering the influence of the emitted energy on the labeled cells. In addition to the value of the photon energy, the potentially harmful effect on cells is also influenced by the type of corpuscular radiation associated with the photon emission and the radio-sensitivity of the investigated cells.

The most frequently used SPECT radioisotopes have a half-life between 6 h and 8 days, which allows images to be acquired over a moderately long time scale. Additionally, SPECT radionuclides are more commonly available than PET radionuclides because SPECT radionuclides are usually eluted from a small portable generator. In turn, most PET isotopes can only be produced on a cyclotron, which means that large-scale infrastructure is required to produce them, making them much more expensive. The average cost of SPECT radiopharmaceuticals is about ten times lower than those for PET [30].

Numerous PET radionuclides may be incorporated into the imaging tracers. The ideal radionuclide for PET imaging should

---

**Fig. 1.** Schematic presentation of the SPECT and PET scanners and their imaging modalities.
emit short-range, low-energy positrons with an abundance of 100%, and lack of gamma rays with energies close to the 511 keV, generated during positron annihilation. Fluorine-18 $^{[18]F}$, for example, is such a PET radionuclide, and thus radiotracers tagged with this radioisotope exhibit the most favorable features for PET imaging, however, with a half-life of 109.8 min is only effective for imaging up to a few hours after administration. Thus, for specific applications that require longer term tracking of administered agents, including some which are routinely clinically applied for SPECT imaging, alternative isotopes with longer half-lives are required. When considering the choice of an isotope, it is important to consider the radiation dose to the patient, as longer exposure times to a given amount of radioactivity will lead to a higher overall radiation dose. As a result, the best practice is to select radioisotopes with half-lives that are tailored to the optimum biodistribution time of the proposed radiotracer. Additionally, overall patient radiation dose for tracers based on longer-lived radioisotopes can be reduced by minimizing the total amount of injected activity although this requires compensation through the use of modern measuring devices or extension of scan acquisition time. Also - unlike $^{[18]F}$, many radioisotopes, such as gallium-$^{68}$ $^{[68]Ga}$, zirconium-$^{89}$ $^{[89]Zr}$, and iodine-$^{124}$ $^{[124]I}$, release large amounts of high-energy prompt gamma rays that may cause scattering artifacts in the positron energy range thus leading to suboptimal overall quality and quantitative accuracy of PET imaging. Despite these drawbacks, there is still a role for radionuclides other than $^{[18]F}$ and many have been successfully used in PET imaging $^{[12,13,31,32]}$. Most commonly used PET isotopes are produced employing a cyclotron apparatus, and are usually short-lived isotopes in comparison to SPECT isotopes. Isotope lifetime may thus represent a key issue to be addressed as a function of the desired probe effect. Adequate time period must be provided for the radioisotopes in medicine for diagnostic tests in order to lose their radioactivity through natural decay, and the shorter the half-life the sooner this point will be achieved. In addition, it may be preferable to minimize the radiation dose delivered to the patient during the test or it might be desirable to repeating the test at intervals without concern for residual activity in the body from the previous test. On these accounts, a short-lived radioisotope might be preferable to a long-lived one. In contrast, in several specific cases, the short half-life of some of the most commonly exploited PET radioisotopes may hinder long-term monitoring of the radionuclide fate inside the body. The recent development of long-lived positron emitters, including copper-$^{64}$ $^{[64]Cu}$, $^{[89]Zr}$, $^{[124]I}$, and vanadium-$^{48}$ $^{[48]V}$ have paved the way for new applications of PET imaging such as the long term tracking radiolabeled cells to be explored.

3. Labeling strategies of immune cells for tracking in vivo with nuclear imaging

Live tracking of immune cells using nuclear imaging involves the detection of radioisotope-labeled cells. There are two major cell labeling techniques for nuclear imaging: i) direct cell labeling with radiotracers or ii) indirect cell labeling involving the expression of an imaging reporter gene in target cells.

3.1. Direct cell labeling

Radiotracer-based direct labeling of immune cells is usually applied in the context of nuclear imaging. It is a quite straightforward technique that is performed under in vitro conditions with little influence on cell behavior, including cell viability and migration $^{[8,18,20,24]}$. There are different types of radiotracers suitable for cell labeling, sharing one basic physical property consisting of a radionuclide that emits externally detectable radiation. The radiotracers, used for direct cell labeling, may be incorporated into the

| Table 2 | List of radionuclides routinely used for planar gamma-scintigraphy/SPECT or PET and their characteristics. |
|---------|------------------------------------------------------------------------------------------------------|
| **Radionuclide** | **$T_{1/2}$** | **Decay** | **$E_{\text{max}}$ (keV)** | **Production method** |
| planar gamma scintigraphy/SPECT(gamma emitters) | | | | |
| $^{[99m]Tc}$; Technetium-99 m | 6.01 h | IT, $\beta^-$ | 140 | Generator |
| $^{[123I]}$; Iodine-123 | 13.22 h | EC, $\beta^-$ | 159 | Cyclotron |
| $^{[111In]}$; Indium-111 | 2.80 days | EC | 171, 245 | Cyclotron |
| $^{[131I]}$; Iodine-131 | 8.02 days | $\beta^-$ | 364 | Cyclotron |
| PET (positron emitters) | | | | |
| $^{[11C]}$; Carbon-11 | 20.38 min | $\beta^+$ | 961 | Cyclotron |
| $^{[18F]}$; Fluorine-18 | 109.77 min | EC, $\beta^-$ | 1899 | Generator + cyclotron |
| $^{[68Ga]}$; Gallium-68 | 12.70 h | EC, $\beta^-$ | 634 | Cyclotron |
| $^{[89Zr]}$; Zirconium-89 | 78.41 h | EC, $\beta^-$ | 656 | Cyclotron |
| $^{[124I]}$; Iodine-124 | 4.18 days | EC, $\beta^+$ | 2100 | Cyclotron |

IT - isomeric transition; EC - electron capture; $\beta^-$ - beta decay, $\beta^+$ - positron decay.
cell through different processes, and under this criterion, we may divide them into a few groups [10,16,33,34]:

1) binding to a specific receptor
2) undergoing endo/phagocytosis
3) taken up via the pump or ion channel
4) undergoing passive transport across the membrane and trapping in the cytosol
5) being built-in the cell membrane
6) linking to cell membrane proteins

Different radiotracers grouped by the mechanism of direct cell labeling are presented in Fig. 2.

A number of agents for direct cell labeling have been generated, such as indium-111 [111In]oxine, [111In]tropolone, [99mTc]hexamethylpropyleneamine oxime ([99mTc]HMPAO) for planar gamma camera scintigraphy and SPECT imaging, 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), hexadecyl-4-[18F]-fluorobenzoate ([18F]HFB), N-succinimidyl-4-[18F]-fluorobenzoate ([18F]FSB), [64Cu]pyruvaldehydebis(N4-methylthiosemicarbazone) ([64Cu]PTSM), [64Cu]polyethyleneimine ([64Cu]PEI) [35], 5-[124I]-iodo-2-deoxyuridine ([124I]IdU) [36] for PET imaging, and [124I]FIT-(PhS)2Mal for both PET and fluorescence imaging. All these radiotracers directly label cells through one of the abovementioned mechanisms. Tracers such as [99mTc]HMPAO, [111In]oxine, and [64Cu]PTSM are nonspecific cell-labeling agents, which by their lipophilic nature, diffuse across the cell membrane and enter the cell [37–41]. Subsequently, these complexes dissociate and the released radionuclides become trapped within the cell by binding to intracellular proteins. Direct labeling of immune cells with radiolabels can also be achieved through the uptake of radiolabeled probes via a transporter mechanism, including a transmembrane receptor, a channel, or a pump, located on the membrane of the cell. As a single transporter located on a plasma membrane can transport many molecules of a radiotracer, this method of direct cell labeling may lead to amplification entrapment of this tracer in the cytoplasm [42,43]. Finally, direct cell labeling can be achieved through direct binding of the radiotracer to the cell membrane. One example of such radiotracers is [18F]HFB, which binds to cellular membranes via a lipophilic long-chain ester [44]. Another approach of direct cell labeling through the radiotracer anchoring to the cell membrane involves the chemical coupling of [59Zr]desferroxamine-NCS ([59Zr][DBN] [45] or [124I]FIT-(PhS)2Mal [46] to cell membrane-bound proteins.

Direct immune cell labeling provides several benefits, which include fairly simple labeling protocols performed without the requirement of genetic cell manipulation and high sensitivity, enabling detection of small numbers of cells due to the minor background signal. Given these properties, direct labeling methods are easier to translate into clinical practice than indirect labeling approaches. Although direct cell labeling is fairly simple, it has some limitations. One disadvantage of this method is that the radiotracer becomes diluted upon each cell division, which leads to decreased concentrations of the probe per individual cell. Additionally, the radiotracer may be transferred asymmetrically to the daughter cells following cell division or may be released from the cells (e.g., [111In]oxine and [64Cu]PTSM), eventually leading to the disappearance of the signal [12,39,47]. As a consequence, directly labeled cells can be tracked in vivo for only up to a few days. Furthermore, direct-labeling does not enable monitoring of cell biological functions, such as proliferation, activation, or viability, and may evoke changes of cellular characteristics after radiotracer uptake. Finally, the adoptively transferred, radiolabeled dead cells may be engulfed by the phagocytic cells leading to the generation of an unspecific signal. To overcome the limitations, reporter-based indirect labeling techniques for live-cell tracking have been developed. These approaches enable the detection of reporter gene-expressing, live immune cells with nuclear imaging techniques following administration of a specific radiotracer [12,13,48].

3.1.1. Tracking of directly labeled immune cells with planar gamma scintigraphy and SPECT imaging

The use of immune cells directly tagged with radioisotopes can be performed in vivo by live tracking of immune cells with planar gamma scintigraphy and SPECT imaging is currently an accepted procedure, and many labeling techniques have been developed for this purpose [49]. Although live tracking of directly radiolabeled white blood cells with planar gamma scintigraphy is routinely used in clinical settings [6], recent progress has focused on the more technologically advanced SPECT imaging in the majority of preclinical and clinical immune cell tracking studies.

Immune cell labeling with direct methods for planar gamma scintigraphy and SPECT imaging relies on radiotracers that are mainly chemical complexes of two radionuclides, namely [111In] and [99mTc].

Direct immune cell labeling with [111In]-based radiotracers. [111In] is a commonly used radioisotope, which, thanks to its long half-life, enables imaging for up to 96 h post-injection (Table 2). It is produced in a cyclotron via the [111Cd(p,n)111In] or [112Cd(p,2n)111In] reactions and decays with a 2.81 day half-life via electron capture to the nuclide [111Cd]. [111In] emits gamma radiation at 171.3 keV and 245.4 keV, which makes it applicable for both planar scintigraphy and SPECT. The only stable state of oxidation in aqueous conditions is In(+III), which is a hard Lewis acid preferring to coordinate to hard amine-N and carboxylate-O Lewis bases, and
it has a high affinity for water making its complexes susceptible to hydrolysis. As a result, high coordinate polyamino acids such as EDTA, DTPA, DOTA, TACN are most frequently used as In(+III) chelators for radiochemical applications to maximize complex stability. In(+III) complexes can form with coordination numbers varying from 4 to 8 and can exhibit a wide variety of coordination complexes and geometries as detailed in these excellent reviews [50,51]. However, for cell labeling tight irreversible binding of the radiometal by the chelating ligands is not always required. One established labeling strategy is to employ metastable lipophilic complexes, which diffuse across the cell membrane, carrying the radiometal with them, and then dissociate inside the cells causing the radiometal to become trapped intracellularly [37,52,53] (Fig. 2). With this approach, highly stable complexes are not desired as there would be no trapping mechanism and the activity would leak out of the cells after labeling.

As described above, [111In] complexes have been at the forefront of the development of cell labeling for in vivo imaging using this strategy. The most prominent example is [111In]oxine [54], which in 1985 was approved by the FDA for leukocyte scintigraphy. The oxine ligand (8-hydroxyquinoline) is lipophilic but retains enough water solubility to react with metal ions in an aqueous solution. It reacts by losing a proton to become an anionic N,O-chelate enabling the formation of neutral lipophilic complexes, which can be readily purified by biphasic extraction into organic solvents followed by solvent evaporation. In the case of In(+III) a hexadentate tris(oxinato)indium(+III) complex is formed with a pseudo octahedral geometry [55] (see Fig. 3).

Initial approaches of immune cell tracking with [111In]-based radiotracers took place in the 70-ties. Segal et al. radiolabeled leukocytes in vitro with [111In]oxine and administered them to patients with various inflammatory diseases: gut abscesses, bacterial endocarditis, rheumatoid arthritis, pyogenic infection. In each case, a high signal was detected in the inflammatory areas using planar gamma-scanigraphy [54]. This early study gave rise to further research, which established [111In]oxine leukocyte scintigraphy or SPECT/CT as a practical and very accurate technique identifying inflamed tissues. Currently, not only rodents are used as an animal model in cell tracking studies employing this tracer. Afzelius et al. labeled a fraction of leukocytes with [111In]oxine, yielding 57.7% – 69.7%, and administered it intravenously to pigs with inflammatory lesions caused by Staphylococcus aureus. The aim of the experiment was to compare the efficacy of osteomyelitis detection by radiolabeled leukocytes and several pure radiotracers. Although 111In-leukocytes accumulated in 79% of inflammatory affected regions, the effectiveness in the case of 18F-FDG PET was 100%, which made this method more reliable [40]. Nowadays, the [111In]oxine labeled leukocyte method is used in humans, for example, to diagnose inflammatory conditions of the urinary bladder [41].

The development of successful immune cell-based anticancer therapies requires a deep understanding of in vivo biodistribution and antitumor activity of immune cells upon administration. Nuclear imaging research has significantly improved our knowledge about immune cell-based therapies against cancer by non-invasive and real-time tracking of immune cells and by visualization of their anticancer activity in numerous preclinical and clinical studies [2]. Noninvasive tracking of directly labeled immune cells using [111In]oxine has been used to trace target tumors. For example, in 20 patients with different lymphatic malignancies and a perceptible lymph node enlargement, in vivo migration of leukocytes labeled with [111In]oxine was studied in planar scintigraphy. Targeting of those cells to lymph nodes was observed in all patients suffering from Hodgkin's lymphoma or high-grade lymphoma, although, in the case of patients with low-grade lymphomas, effective targeting was observed in less than half of the patients [56]. SPECT imaging can also be useful for the evaluation of targeting directly radiolabeled adoptive T lymphocytes to tumors. CD8+ Tc lymphocytes (CTLs) with affinity to the Melan-A melanoma antigen were labeled with [111In]oxine, administered to patients, and their targeting was evaluated using whole-body counter and static gamma camera imaging. Nuclear imaging allowed the detection of CTLs at metastatic sites, but there was also a signal in the liver, lungs, and spleen [57]. In another study, Pittet et al. labeled mouse T-cells expressing the hyaluronan-characteristic T-cell receptor with [111In]oxine and injected them intravenously to mice with HA+ CT44 and HA−CT26 tumors. Labeled CTLs were detectable in HA+ CT44 tumors within 24 h of administration, and their numbers increased throughout the study. By comparison, there was very little homing of the labeled CTLs to the HA−CT26 tumors, suggesting that the tumor-targeting of these T-Cells was mainly TCRs mediated [58]. In a different study, human CAR-T cells were radiolabeled with [111In]oxine to evaluate their trafficking in mice using SPECT/CT when different routes of cell injection were used. Compared to subcutaneous (S.C.) and intraperitoneal (I.P.) injections, optimal biodistribution was obtained after intravenous (I.V.) administration [59]. Finally, γ T cells, which are a specific type of T cells capable of identifying and killing neoplastic cells without involvement of MHC molecules, were directly labeled with [111In]oxine and adoptively transferred to mice with 4 T1 mammary adenocarcinoma (a murine model of triple-negative breast cancer). SPECT and CT study of adoptively-transferred γ T cells

![Fig. 3. [111In]oxine formation reaction and structure.](image-url)
has revealed that these cells targeted mouse tumors, and efficiently reduced their size [60].

NK cells are another type of immune cell with substantial anti-tumor activity, and thus NK cell-based anticancer therapies have emerged as a promising therapeutic approach for cancer treatment. Nuclear imaging has contributed to our understanding of therapeutic approaches focused on the administration of tumor-infiltrating NK cells [61]. In a study by Meller et al. SPECT imaging was employed to investigate the biodistribution and kinetics of in vitro expanded allogeneic NK cells [62]. For this purpose, NK cells were labeled with $^{111}$In-oxine and administered with a tenfold excess of unlabeled cells to three patients with renal cell carcinoma. SPECT imaging revealed that shortly after transfusion $^{111}$In-oxine labeled NK cells were primarily detected in lungs, but within the first 24 h they were redistributed from lungs to liver, spleen, and bone marrow. Moreover, 24 h after transfusion $^{111}$In-oxine labeled NK cells could be observed in two out of four large metastases, which were confirmed by high glucose uptake with $^{18}$FFDG-PET. In another study, SPECT imaging was used to compare the migration of $^{111}$In-oxine-labeled autologous NK cells to liver metastasis in colon carcinoma patients upon administration either via the systemic (intrahepatic) or locoregional (intraarterial) routes [63]. SPECT imaging analysis revealed that NK cells injected intrahepatically localized primarily to the liver, whereas localization of intraarterially injected NK cells was limited to the spleen and liver. Moreover, migration of NK cells to liver metastasis was observed only after intraarterial injections. The $^{111}$In-oxine radiotracer was also successfully used in the biodistribution and tumor targeting study of NK cells generated from umbilical cord blood hematopoietic progenitor cells (UCB-NK cells) and adoptively transferred in immunodeficient NOD/SCID/IL2Rγnull mice [64]. Using SPECT imaging, Cny et al. demonstrated that $^{111}$In-oxine-labeled UCB-NK cells migrated to liver, spleen, and bone marrow within 24 h after transfusion, and most importantly a single administration of UCB-NK cell impaired the growth of bone marrow-residing human leukemia cells injected intra-femorally in mice, leading to increased mouse survival.

Dendritic cells (DCs) induce protective adaptive immunity and thus have been a focus of anticancer vaccines and immunotherapy treatments. SPECT imaging has contributed to our increased understanding of DC biology and DC-based anticancer therapies. In a study by Prince et al. PET and SPECT imaging modalities were employed to track the in vivo migration of monocyte-derived nonmatured DCs (nmDCs) or matured DCs (mDCs). For this purpose, DCs were labeled with $^{18}$FFDG or $^{99m}$TcPMT for PET imaging and $^{111}$In-oxine for SPECT imaging and administered to patients with multiple myeloma via (I.V.), intradermal (I.D.), (S.C.), and intranodal routes [65]. Among tested radiotracers, $^{111}$In-oxine showed reproducible tracking of both types of DCs to regional lymph nodes after either S.C. or I.D. administration, with mDCs showing superior migration to regional lymph nodes. $^{111}$In-oxine-SPECT imaging was also successful in the in vivo monitoring of lymph node migration of $^{111}$In-oxine labeled DCs in a murine breast cancer model (MMTV-Ras). Labeling of DCs with $^{111}$In-oxine, had no adverse effect on DC phenotype or functionality, and most importantly SPECT imaging revealed the presence of $^{111}$In-oxine-labeled DCs in both axillary and popliteal lymph nodes. These results were confirmed with immunohistochemistry and γ-counting analysis [66].

$^{111}$In-oxine binds to the iron transport protein transferrin in blood plasma and so the blood plasma must be removed from patient samples before the cell labeling step, however, this process may affect cell viability. To overcome this problem, other $^{111}$In-based radiolabels such as $^{111}$In-2-mercapto-2-methylpropionic acid (MMP-Merc), $^{111}$In-triomevaline and $^{111}$In-acetic acid (ACAC) were developed [67,68]. Although these radiotracers exhibited effective labeling of leukocytes in a plasma, they did not become commonly applied agents for nuclear imaging of leukocytes in vivo. Nevertheless, it is worth mentioning an experiment in which human blood-derived γδ T cells were labeled with $^{111}$In-triomevaline and then injected I.V. into NSG mice with A375P6.Iuc cell tumors, inoculated I.V., S.C. and I.P. The I.P. model showed the highest γδ T cell uptake of the three examined models [69].

**Direct immune cell labeling with $^{99m}$Tc-based radiotracers.** The promising results obtained with $^{111}$In-labeled leukocytes studies inspired efforts to develop analogous methods of cell radiolabeling with $^{99m}$Tc, which due to its unique physical properties is now the most commonly used radioisotope for gamma-based diagnostics [70]. Moreover, this radioisotope guarantees a high signal-to-noise ratio, enabling the detection of even small numbers of cells. Stable isotopes of technetium do not exist and so most of the Tc used in laboratories is freshly generated from nuclear reactions. The most commonly used isotopes $^{99m}$Tc is produced in a generator by the decay of the longer-lived isotope – $^{99}$Mo. The half-life of $^{99m}$Tc is 6 h and it decays with 12% internal conversion and 88% gamma photon emission at 140 keV, making it excellent planar gamma scintigraphy and SPECT imaging isotope (Table 2). Technetium is available at oxidation states from (-I) to (+VII), but the most stable states are (+VII) and (+VI). The lower oxidation states (+I), (+II), and (+III) need to be stabilized with chelating ligands to prevent technetium hydrolysis products from forming, which interfere with subsequent labeling efficiencies. $^{99m}$Tc is eluted from a $^{99}$Mo generator as $^{99m}$TcO$_4$- (+VII). This needs to be reduced to lower oxidation states with an in situ reducing agent, commonly SnCl$_2$, to form coordination complexes with chelating ligands. Tc can form stable complexes with both hard and soft Lewis bases as demonstrated by the diversity of the commercially available $^{99m}$Tc imaging agents, such as Myoview P4O2, Sestamibi G6, Dextrazine SPECTNema-303, and Technescan MAG3-N3S.

Although a variety of chemical complexes of $^{99m}$Tc for direct cell labeling have been designed, the most commonly used $^{99m}$Tc-based radiotracers, initially dominating in planar scintigraphic techniques and now mainly used in SPECT imaging, is $^{99m}$Tc-HMPAO. This N4 coordinating ligand, also known as exametazime is sold in kit form with the SnCl$_2$ reducing agent under the trade name Ceretec®. The kit is reconstituted with freshly eluted $^{99m}$TcO$_4$- to form $^{99m}$Tc-HMPAO via the reaction presented in Fig. 4. The resultant lipophilic complex is passively absorbed across the cell membrane and is trapped within cells via a combination of reduction to a hydrophilic complex and binding of the complex to non-diffusible proteins and cellular organelles [71].

Comparison of $^{99m}$Tc-HMPAO and $^{111}$In-oxine biodistribution shows significant differences. $^{99m}$Tc-HMPAO has significant intestinal activity due to its biliary secretion route [71]. This makes $^{99m}$Tc-HMPAO less effective in the case of cell tracking within the abdomen. The low energy emission properties of the radionuclide $^{99m}$Tc can be used at a higher dose than $^{111}$In which confers an advantage for imaging small parts of the body. The disadvantage is its relatively short half-life giving only a short period for the tracking of immune cells. $^{99m}$Tc-HMPAO is mainly applied in imaging of infections [6]. In 1990, 19 patients suffering from inflammatory diseases were injected with leukocytes labeled with $^{99m}$Tc-HMPAO and imaged with a gamma camera [72]. This study achieved 100% specificity, 93% sensitivity, and 95% accuracy. This was later repeated by Reynolds et al. who obtained similar results: sensitivity 92.8%, specificity 93.3%, and accuracy 93.2% [73]. In 1994 Peters et al. concluded that injection of autologous $^{99m}$Tc-HMPAO-labeled white blood cell fraction should be the top compound for the diagnosis of inflammatory bowel disease (IBD) and most forms of acute sepsis [74]. Mansfield et al. attempted to compare the diagnostic potential of autologous leukocytes labeled with $^{111}$In-triomevaline and $^{99m}$Tc-HMPAO for IBD [75]. They observed a
close correlation between the fecal excretion of $[^{111}\text{In}]$ and the result of the $[^{99m}\text{Tc}]$ image analysis, which confirms the usefulness of these radiotracers in the context of determining inflammatory bowel activity. A diagnostic method involving the venous leukocyte fraction is also used today in the clinics. Migliari et al. reviewed 490 studies with labeled leukocytes in the context of infection diagnosing (mainly bone and orthopedic implant infections). They concluded, that this method is characterized by its ease of application in routine clinical practice, good cell labeling efficiency (72%) and high-quality images [76], Jorgensen et al. have approached the radiolabeling of the pure lymphocyte fraction and confirmed the effectiveness of lymphocytes for targeting arthritic joints [38]. The research aimed at rheumatoid arthritis (RA) visualization was also performed with the use of autologous blood-derived monocytes which upon labeling with $[^{99m}\text{Tc}]$HMPAO, were re-infused to RA patients. Scintigraphy [77] or SPECT imaging [78] of the hands and feet of RA patients revealed clear images of re-infused, radiolabeled monocytes localized to the inflamed joints. Importantly, the biodistribution of $[^{99m}\text{Tc}]$HMPAO-labeled monocytes is similar to that of $[^{99m}\text{Tc}]$HMPAO-labeled white blood cells and might therefore be employed for live monitoring of antirheumatic therapy in patients [79]. In 2011 Ruparelia et al. showed significant migration of $[^{99m}\text{Tc}]$-labeled neutrophils to the target tissue in patients suffering from a chronic obstructive pulmonary disease (COPD). $[^{99m}\text{Tc}]$-labeled neutrophils were administered and tracked using sequential SPECT imaging in six COPD patients and three volunteers. The obtained images demonstrated significant levels of neutrophil migration to the lungs in COPD patients. The results corresponded well with a whole-body counter quantitative analysis of $[^{111}\text{In}]$tropolone radiolabeled neutrophils [80]. Lukawska et al. compared the kinetics of autologous granulocytes and eosinophils in healthy human patients. These two populations of leukocytes were radiolabeled with $[^{99m}\text{Tc}]$HMPAO, administered intravenously and SPECT images were taken after 1, 5, 15, 25, and 120 min. Granulocytes and eosinophils showed different distribution patterns to the liver, lungs, and mediastinum. Favorable trafficking of eosinophils to the spleen and bone marrow and neutrophils to the liver was proven [81]. The same team evaluated the targeting properties of neutrophils and eosinophils to the lungs of patients suffering from asthma [82]. The patients were divided into three groups: (1) early allergic responders, (2) early/late allergic responders pre-treated with antigen, and (3) allergic patients treated with steroids. Using the gamma camera, a higher net retention time of eosinophils was observed in the first group of asthma individuals than the non-smoking group from the previous study. Further development of this technique may bring the discovery of a key tool for asthma phenotyping. This observation corresponds with the recent study, in which autologous venous blood eosinophils radiolabeled with $[^{99m}\text{Tc}]$HMPAO were I.V. injected to healthy and obese asthmatic patients, showing higher eosinophil trafficking in the lungs of asthma group patients [83]. Interestingly, it was acknowledged that treating leukocytes with $[^{99m}\text{Tc}]$HMPAO results in the preferential labeling of granulocytes, with the strongest selectivity of eosinophils over other leukocytes, which indicates the utility of this radiotracer application during eosinophil-labeling studies [84]. Pillay et al. observed, that the trafficking of autologous neutrophils labeled with $[^{99m}\text{Tc}]$HMPAO initially occurred in the lungs, over time their number in the lungs decreased and after 24 h they were detectable only in the liver and spleen. Interestingly, the administration of C-X-C chemokine receptor type 4 (CXCR4) antagonist did not affect neutrophils' distributions [85].

$[^{99m}\text{Tc}]$HMPAO was also successfully used for in vivo tracking of specific populations of immune cells such as T cells, DCs, and NK cells in the context of cancer immunotherapy. Sharif-Paghaleh et al. employed SPECT/CT analysis to evaluate the efficacy of DC vaccination by early detection of $[^{99m}\text{Tc}]$HMPAO-labeled CD4 + T cells in draining lymph nodes [86]. Another $[^{99m}\text{Tc}]$HMPAO/SPECT imaging study investigated the lymph node migration of mDCs and immature DCs (iDCs) and the impact of administration route (intradermal versus subcutaneous) on this process. SPECT analysis showed that intradermal administration of $[^{99m}\text{Tc}]$HMPAO-labeled DCs resulted in about a threefold higher migration to lymph nodes than subcutaneous administration, and mDC exhibited higher migration than iDC. DCs were first detected in lymph nodes just 20–60 min after inoculation and the maximum numbers were detected at 48–72 h post inoculation [87]. The $[^{99m}\text{Tc}]$HMPAO radiotracer was also used for labeling and in vivo tracking of lymphokine (IL-2)-activated killer (LAK) cells induced from T cells (T-LAK) and NK cells (NK-LAK) isolated from patients with head and neck carcinoma [88]. $[^{99m}\text{Tc}]$HMPAO-labeled LAK cells were administered back into the respective patients locally into the tumor tissue or via the superficial temporal artery. The administered LAK cells were tracked using a gamma camera. T-LAK cells were retained longer in the tissue than NK-LAK cells, because T-LAK cells were less adherent and less chemotactic to endothelial cells, and exhibited decreased migration through endothelium as compared with NK-LAK cells. Another method of leukocyte labeling with $[^{99m}\text{Tc}]$ involves the phagocytic engulfment of a radiolabel being in the form of a colloid. An attempt has been made to label blood cells with $[^{99m}\text{Tc}]$-stannous oxide colloid ($[^{99m}\text{Tc}]$-SnO$_2$). Although the labeling efficiency was between 80 and 90%, most of the radiolabel was accumulated in phagocytic cells: neutrophils and monocytes. The radiolabeled monocytes were reinjected to the patients with the tentative diagnoses of an abdominal abscess or septic loosening of an endoprosthesis, resulting in visualization of local inflammatory foci [89].
3.1.2. Tracking of directly labeled immune cells with PET imaging

Direct cell labeling with [18F]-based radiotracers. [18F] is the isotope, which is the most commonly exploited for various PET studies. [18F]-based radiotracers generate images of high-resolution due to the high $\beta^+$ decay ratio (97%) and low positron energy (maximum 0.634 MeV). Its main drawback for cell tracking concerns its short half-life of 109.8 min, which impairs complex radiochemistry, the performance of extended in vivo studies, and delivery to PET centers with no radiochemistry facilities. It entails the necessity of easy access to the freshly synthesized radiocompound. The most widely applied radio-compound both in medicine (tumor diagnosis) and cell labeling studies, is [18F]FDG. This molecule is an analog of glucose with a positron-emitting [18F] atom connected to the 2 carbon instead of a hydroxyl group. It is absorbed by live cells, via the GLUT transporters. The family of these membrane-bound proteins consists of 5 subtypes, however, GLUT-1 and GLUT-3 are considered to contribute to the in vivo accumulation of FDG in malignant tumors [90]. In the cytosol, it enters the glycolytic pathway, which leads to its phosphorylation by hexokinase to [18F]FDG-6-phosphate. This molecule is not capable of leaking out from the cell, causing a metabolic trap. But elution of unphosphorylated [18F]FDG which is initially taken up, is a major drawback that results in continuous retention and loss of cell radioactivity. For instance, the cell labeling efficiency decreased in two hours from 89.9% to 62.1% in human stem cells, and from 91.6% to 68.6% in porcine stem cells [91]. In a different study, the labeling efficiency of the fraction of human blood-derived leukocytes decreased from 64% to 75% to 39%–44% after 90 min and eventually to 19% after 240 min [92].

Many types of white blood cells as well as mixed fractions of leukocytes were radiolabeled with [18F]FDG and tracked in vivo. Forstrom et al. showed [18F]FDG uptake mainly by the granulocyte fraction (78.5 ± 1.4%), with significantly lower uptake by the lymphocytes and platelets (12.6 ± 1.9%) [93]. Most studies regarding the tracking of [18F]FDG labeled cells concerned imaging of infections. Pio et al. have proven the feasibility of autologous leukocyte application for visualization of inflammatory foci, both in mice and human patients with inflammatory bowel disease [94]. During another study, a similar method was applied to 49 human patients suffering from various inflammatory diseases. The radiolabeled leukocyte-based PET/CT was more valuable than the conventional [18F]FDG PET/CT in the context of imaging of infection, as this approach reached higher values of specificity and sensitivity [95]. Bhattacharya et al. have proven that [18F]FDG labeled autologous leukocytes efficiently target infected fluid accumulations in acute pancreatitis, finding this method reliable in diagnosing this disease in human patients [96]. In a systematic review, Meyer et al. summarized the effectiveness of [18F]FDG labeled leukocytes in diagnosing infections. It has been concluded, that when comparing the effectiveness of this method to classical techniques: CT, MRI, and even [18F]FDG-based PET, the obtained results indicate higher diagnostic performance and claim, that [18F]FDG labeled leukocyte-based method should be routinely applied in the clinics. Importantly, no adverse effects were observed in any human patient [97].

In our research, we studied the ability of mouse macrophages (the mouse macrophage cell line RAW 264.7) to migrate to metastases-bearing lungs (4T1 model). Plain [18F]FDG was injected into the mice that were subjected to the PET study within 1 h. The short decay time of [18F] allowed us to administer macrophages labeled with [18F]FDG intravenously into the same mice on the same day and track their distribution. PET analysis showed focal signal from the lungs in mice with lung tumors that received labeled macrophages and no signal in the lungs in mice that received [18F]FDG (Fig. 5) [98].

Another [18F]-based radiotracer is [18F]4-fluorobenzamido-N-ethylamino-maleimide ([18F]FBEM). This compound undergoes a completely different labeling reaction - unlike [18F]FDG, it covalently binds to functional groups of the cell membrane surface and more specifically – to exofacial protein thios (EPT). The limitation of this method is that was found to be a large variation in the labeling efficiency between cell types that couldn’t be explained by the variation in EPT levels alone. Jurkatz and SaOS-2 cells were radiolabeled at a fairly low level (7.7 and 7.1% respectively), whereas primary T lymphocytes at a relatively high level – 60.5% [99]. The in vivo PET tracking of these cells was performed.

Fig. 5. Fused PET/CT images presenting the distribution of intravenously injected [18F]FDG and RAW264.7 macrophages radiolabeled with [18F]FDG in breast cancer lung metastases. A - surface rendering (SR) of fused PET/CT images obtained after [18F]FDG administration (imaged 1 h post-injection); primary tumor (arrow), bladder, heart, and eyes are visible; the signal was not detected in lungs. B - SR (left) and maximum intensity projection (MIP) (right) of PET/CT images followed prior administration of RAW264.7 macrophages radiolabeled with [18F]FDG (3 h post-injection); in SR images, green color represents PET signal; in the MIP image, PET signal intensity is reflected by the color bar; the tumor was not visualized, but strong, the asymmetric signal from lungs was detected; the signal from the bladder indicates that part of the radiotracer was eluted. C - schematic location of lung metastases (upper image) and representative histopathological image of the tumor focus from examined sample (lower image). The PET/CT images were generated using PMOD software (PMOD Technologies LLC, Zurich, Switzerland).
successfully, following intravenous injection of the cell suspension to the naïve C57BL/6 mice, and the signal was detected mainly in the spleen. Thus, this method has promise for certain cell types evaluation of labeling efficiency and label retention is required for each new cell type to be labeled. The most important feature of this method compared to [18F]FDG labeling is distinctly lower radiotracer retention. There was also an approach of labeling murine spleen-derived leukocytes with [18F]FBEM and evaluation of their recruitment to the lungs with fibrosis in mice. Interestingly, PET images showed greater and faster trafficking of leukocytes in the mice treated with bleomycin than control mice [100]. An efficient and quick procedure of automated radiosynthesis of [18F]FBEM was recently introduced by Lim et al. [101].

The [18F]-containing radiolabel that demonstrates a cell incorporation mechanism similar to that observed for fluorescent dyes, is hexadecyl-4-[18F]fluorobenzoate ([18F]HFHB). It is a novel, lipophilic derivative, which is incorporated into the cell membrane but does not enter the cytoplasm. The labeling efficiency was evaluated so far only in rodent mesenchymal stem cells - after 30 min it reached 25% and cell viability was found to be > 90%, furthermore, there was a retention of radiotracer in the cells > 90% over 4 h. The labeling procedure was quick and simple [44]. However, Kiru et al. observed a certain drawback of this method. Although bulk gamma counting showed higher MDA-MB-231 labeling efficiency compared to [18F]FDG (it was 2.5 fold greater), the single-cell imaging with radioluminescence microscope revealed relatively weak binding of [18F]HFHB to living cells and high binding to membrane fragments from dead cells [102]. Zhang et al. compared labeling of the human circulating progenitor cells (CPC) with this radiotracer and [18F]FDG and found that the cell labeling with [18F]HFHB as compared with [18F]FDG was more efficient (23.4% ± 7.5% vs. 7.6% ± 4.1%) and stable (88% ± 6.0% vs. 26.6% ± 6.1% after 4 h). The CPC radiolabeling with [18F]HFHB resulted in a more effective, accurate, and stable way of quantifying cell migration as shown in a rat myocardial infarction model in vivo [103].

Direct cell labeling with [64Cu]-based radiotracers. [64Cu] is a theranostic radionuclide endowed with the remarkable property of releasing both β− (17.6%) decay for PET imaging and β+ (38.5%) decay for therapeutic applications [104,105]. The maximum β+ emission energy (656 keV) and the mean positron range (0.7 mm) compare favorably to [18F] (250 keV, 0.6 mm) [106]. [64Cu] has a half-life of 12.7 h allowing for the tracking of longer-lived biological processes over 1 to 2 days. Copper is a group 11 transition metal element that is capable of accessing oxidations states (+I), (+II), and (+III) although in aqueous solutions Cu(+II) predominates. Copper is a borderline Lewis acid [107], meaning it is a versatile metal that can form stable complexes with a wide variety of donor atoms including hard Lewis bases such as nitrogen and oxygen, and soft Lewis bases such as phosphorus and sulfur. Cu(+II) complexes commonly take a distorted octahedral form with a coordination number of 6. Cu(II) complexes are typically very labile meaning ligands can rapidly exchange [108,109] leading to a breakdown of complexes and release of the metal ion from labeled constructs. As a result, careful design of multidentate and macrocyclic ligands are required for [64Cu] radiolabeling strategies when metal ion release is not desired such as in the radiolabeling of antibodies, peptides, or other targeting moieties. This an extremely broad topic and has been the subject of many recent comprehensive reviews [52,34,105,108–114]. For cell labeling applications alternative strategies can be applied where the release of the metal from the ligand can be of benefit. For example, [64Cu]PTSM, due to its lipophilic properties, passively diffuses through the cell membrane. When it enters the cytoplasm, the [64Cu]PTSM breaks down releasing free [64Cu], which is bound by cellular proteins and the neutral PTSM disperses back out of the cells [34]. Adonai et al. performed efficient murine splenic lymphocyte labeling and tracked their systemic migration in a mouse model. Cell monitoring for over 18.9 h revealed that the lymphocytes initially traveled through the lungs and then accumulated in the spleen and liver [39]. Park and co-workers compared two radiolabels in the context of leukemia cells (K562-TL): [124I]FIAU and [64Cu]PTSM claiming that the second one is more efficient, because of its markedly higher labeling efficiency and lower in vitro but also in vivo efflux [115]. Griesinger and collaborators labeled in vitro murine OVA Th1 lymphocytes, reaching labeling efficiency of 6.5% – 9%, however, retention studies indicated that only after 5 h, 47% of added [64Cu]PTSM was still observed in the cells, however, after 24 h it was only 14%. They injected cells I.P. or I.V. to mice with airway hyperreactivity (AHR) induced by OVA and also to naïve control mice. The cells were targeted specifically to the hyperactive sites and remained visible for over 48 h. These authors were able to detect 60 000 [64Cu]-labeled Th1 lymphocytes in a single lymph node 20 min after intraperitoneal administration [116]. In an alternative study [64Cu]tropolone was evaluated as a radiolabel for the human WBC fraction. Although the initial labeling efficiency was encouragingly high (83%), the rapid elution of radionuclide (nearly 50% after 4 h and > 70% after 24 h) makes it impractical for potential application in this setting [117]. Similar approach to white blood cell tracking was introduced by Soca et al. Various radiotracers, including [64Cu]oxinate and [64Cu]tropolone were synthesized using specific anion-exchange cartridges. This novel method allows for the synthesis of oxinate and tropolones in small volumes, suitable pH and the reaction is characterized by high yield (94.8% ± 2.4 for tropolone and 76% ± 20.3 for oxine) and high extraction efficiency (>94%). In this study, the animal model was BALC/c mouse and the targeted pathologies were muscle infection caused by intramuscular (I.M.) inoculation of P. aeruginosa and muscle sterile inflammation induced by I.M. injection of turpentine oil. WBC fraction isolated from BALB/c mice was successfully radiolabeled with [64Cu]oxinate and [64Cu]tropolone, reaching 57.1% ± 8.6 and 95.6% ± 2.6 labeling efficiency, respectively. The fractions of radiolabeled WBC were reo-orbitally injected and the series of PET scannings was performed. Clear signal indicating the presence of labeled leukocytes was detectable at sites of infection and inflammation [118].

To label cells with the [64Cu]-containing radiolabel, another mechanism was employed. An organic polymer, polyethylenimine (PEI) was used to create a stable complex with [64Cu]. Interestingly, this reaction was feasible without using a metal chelator. PEI binds to anionic heparin sulfate proteoglycans presented on the cell membrane and is transported into the cell via endocytosis [119]. Li et al. synthesized [64Cu]PEI and managed to radiolabel U87MG cells, however, the labeling efficiency was low (20.5% compared to 42.8% using [64Cu]PTSM in the same study), moreover, the efflux reached 61% at 27 h. In general, [64Cu]PEI demonstrated a comparable cell distribution pattern to [64Cu]PTSM - initially, the cells were retained in the lungs, after 20 h redistributed to the liver but radioactivity was also found in the kidneys [35].

To overcome the problem of low radiotracers’ retention, we developed a system in which [64Cu] was incorporated within the apoferritin cage and this complex was subsequently loaded by endocytosis to macrophages to track their distribution in lung-tumor-bearing mice. We called this diagnostic conjugate “MRIC” – macrophage radioisotope conjugate. The [64Cu] apoferritin incorporation procedure was previously proposed by Wang et al. [120]. Briefly, 1 ml apoferritin solution in acetate buffer 50 mM at 2 mg/mL concentration, pH 6.0, was mixed with 1 ml of a [64Cu] solution (about 1 GBq/mL in 0.5 M HCl) neutralized with concentrated sodium carbonate (Na2CO3). The solution was placed under stirring (Vortex) for 2 min and then 30 min in a shaking heater at 45 °C. Thereafter, 100 μl of a 0.1 M sodium sulfite solution was added to the reaction and warmed again at 50 °C for half an hour. Finally,
the reaction mixture was exchanged for PBS buffer using a Vivaspin 500 concentrators PM30 in an Eppendorf centrifuge at 2000 g (4500 rpm for rotor MSC-6000) for 10 min. This was repeated two further times and the protein was recovered, diluted to the desired concentration for cell loading, and sterile filtered (overall protein recovery about 1 mg). Such method allowed for safe and fast labeling of the apoferritin protein with $^{64}$Cu with negligible leaking of the isotope, which was rendered water-insoluble inside the cavity after transformation onto its sulfide derivative. Further optimized human apoferritin mutants have been recently obtained that allow for faster and efficient $^{64}$Cu incorporation [121].

To be able to track RAW264.7 macrophages longitudinally in tumor-bearing mice (CT26 colon cancer cells injected on the thigh according to the procedure already described [122]), we loaded them with the complex of apoferritin and $^{64}$Cu and injected them into the tail vein. Using PET/CT we observed a specific accumulation of the radioactive signal in the tumor in a time-dependent manner showing macrophage trafficking to this site (Fig. 6). This study showed that even a single administration of autologous or allogeneic macrophages loaded with apoferritin-$^{64}$Cu significantly reduced the number of lung tumors in mice. Direct cell labeling with $^{89}$Zr-based radiotracers. $^{89}$Zr is a PET radioisotope with a distinctly longer half-life (78.4 h) than those previously mentioned. However, only 22.7% of its radiation is $\beta^+$. The mean $\beta^+$ emission energy is 396 keV and the mean positron range (1.3 mm) is higher than for $^{18}$F (0.6 mm) [106]. Besides, $^{89}$Zr also exhibits a 77.6% electron capture decay pathway to $^{89m}$Y which decays by emission of a single gamma quantum at 909 keV. Despite the slightly less favorable imaging properties of $^{89}$Zr, its long half-life makes it a very useful tool for immuno-PET imaging, and efficiently performed labeling procedures allow in-vivo cell tracking for up to 15 days [123].

Zirconium is a group 4 transition metal element, existing mainly in the (+IV) oxidation state. Because of its small size and high charge, Zr(+IV) is considered to be a hard Lewis acid meaning it preferentially coordinates to hard Lewis bases like oxygen and nitrogen [107]. Zr(+IV) has a preference for 8 coordinate complexes as demonstrated by Kathirgamanathan and co-authors who prepared and crystallized zirconium tetrakis(8-hydroxyquinolinolate) for the preparation of organic light-emitting diodes [124]. The formation reaction and structure of $^{89}$Zroxinate$_4$ [125] is given in the Fig. 7.

This work was of interest to the nuclear medicine community as 8-hydroxyquinolinolone (oxine) has been employed since the mid-1970s for radiolabeling cells with $^{111}$Inoxine for scintigraphy studies and SPECT imaging. In the case of this compound, the cell labeling procedure is analogous to the other lipophilic agents (HMPAO, PTSM, tropolone). They passively diffuse across the cell membrane, and then the isotope-chelator complex breaks down in the cytosol in a reduction reaction and the isotope binds to intracellular proteins. $^{89}$Zroxinate$_4$ was first synthesized by Charoenphun et al. in 2014 and the first approach of cell labeling with $^{89}$Zroxinate$_4$ was performed using human leukocytes and the following cell lines: breast cancer cells (MDA-MB-231), murine macrophages (J774), and murine myeloma cells (eGFP-5 T33). Labeling efficiency of these cell lines was in the range of 40 – 61%, the retention measured after 24 h upon labeling was high (from 71% to 90%) and cell viability > 90%, without a significant decrease after 24 h [126]. In another study, Sato et al. attempted to label BMDCs and naïve splenic T lymphocytes to evaluate their tumor-targeting properties in the mouse model. Interestingly, DC labeling efficiency was twice higher (>40%) than for lymphocytes (10% for naïve and > 20% for activated by TCR stimulation). PET tracking of intravenously injected cells was performed for 7 days.
PET images showed that DCs were mainly distributed to the liver and spleen after passing through the lungs and Tc lymphocytes were mostly trafficked in the lymph nodes and spleen. The most interesting outcome from this study was that only a small fraction of these lymphocytes targeted the tumor [127]. A similar distribution was also observed in our studies [123,128], which corresponded well with recent outcomes. Watson et al. isolated murine spleen and lymph node-derived CD8+ T cells and radiolabeled them with freshly synthesized $[^{89}\text{Zr}]\text{oxinate}_4$ reaching 18–20% labeling efficiency and > 90% cell viability. After intravenous injection of 8 – 17 mln lymphocytes to C57BL/6j mice with subcutaneously inoculated B16F10 tumors, PET imaging was performed. The signal from the tumors was observed within the first-hour post-injection and was gradually increasing alongside the tumor growth until reaching the final time-point of imaging, which was 188 h. This shows immediate diapedesis of T cells from the vascular system and their migration to solid tumors. This phenomenon also gradually increases over time [123].

Recently, Man et al. evaluated the targeting of γδ T cells to engrafted mouse breast tumors. This specific subtype of lymphocytes acts as a very promising agent in adoptive immunotherapy when considering their tumor-infiltrating abilities, cytotoxicity, and antigen-presenting properties. The $[^{89}\text{Zr}]$-labeled cells were administered to the tail vein of female SCID/Beige and NOD SCID GAMMA (NSG) mice inoculated with cancer cells (MDA-MB-231, hNIS-GFP) via intramammary administration. Tumor targeting of lymphocytes was significantly increased in the case of injection of alendronate-loaded liposomes, suggesting that they increase leukocytes' migration to the tumor [129]. Adoptive therapy with chimeric antigen receptor T cells (CAR-T) has recently become a very exciting clinical concept in human oncology [130]. Weist et al. conducted a preclinical study involving the transplantation of $[^{89}\text{Zr}]\text{oxinate}_4$-labeled human CAR-T cells to NSG mice, to evaluate their targeting of glioblastoma brain tumors (cells administered intravenicularly) and subcutaneously inoculated prostate tumors (cell administered intravenously). That was the first approach of human lymphocytes radiolabeling with this tracer. As expected, cell labeling efficiency was high (75%) and radionuclide retention measured after 6 days was satisfying (60%). The cells injected intravenously were distributed to the tumor over 6 days as shown with PET imaging, and the ones that were intratumorally injected were visible only in the region of the tumor for the whole study [131]. Concluding, the efficacy of this radiotracer in tracking many types of cells have been confirmed in numerous preclinical studies, not only in mice models but also in non-human primates [132]. Together these exciting preclinical results have focused efforts to translate $[^{89}\text{Zr}]\text{oxinate}_4$ cell labeling techniques to the clinic as exemplified by the development of a kit formulation for the preparation of $[^{89}\text{Zr}]\text{oxinate}_4$ [133] and the publication of a guide to producing $[^{89}\text{Zr}]\text{oxinate}_4$ labeled WBC to US Pharmacopeia standards [134]. An unconventional approach to using $[^{89}\text{Zr}]\text{oxinate}_4$ in cell tracking studies was taken by Sato et al. who chose the rhesus macaque as an experimental model. Macaques' autologous NK cells were ex vivo radiolabeled with $[^{89}\text{Zr}]\text{oxinate}_4$. Importantly, the labeling step did not affect the phenotype, function nor viability of the cells. The macaques were intravenously injected with radiolabeled NK cells, which were PET tracked for 7 days of the experiment's duration. Significantly, the monkeys were treated with a continuous I.V. infusion of deferoxamine, starting just before the cells’ administration. The role of deferoxamine was to chelate the eluted zirconium what leads to the renal excretion of the radionuclide and prevents its accumulation in the bones. PET imaging revealed the initial accumulation of NK cells in the lungs and subsequently, they were distributed to the liver, spleen, and to a lesser extent, bone marrow. The most important observation from this study appears to be the confirmed safety of this type of adoptive cell transfer method. The fact of finding no side effects in a species close to humans allows us to consider this method as applicable in medicine [135].

The development of chelator chemistries for $[^{89}\text{Zr}]$ to enable the radiolabeling of antibodies for immuno-PET imaging is an extremely fertile field of research and there have been several excellent reviews covering recent developments in this area [109,112,136–139]. The most commonly used methodology is a two-step process whereby a deferoxamine based bifunctional chelator (DFO-Bz-NCS) is covalently bound to amine groups of lysine side chains on the surface of the antibody through NCS coupling by $[^{89}\text{Zr}]$ chelation to the DFO in aqueous conditions at neutral pH [140]. Interestingly, DFO has also found application in the effective radiolabeling of human hemoglobin, where the chelator is bound to a cysteine residue at position 93 [141]. The formation reaction and structure of $[^{89}\text{Zr}]\text{DBN}$ (or $[^{89}\text{Zr}]\text{DFO-NCS}$) is presented in the Fig. 8. Notice that as a hexadentate ligand DFO does not fully satisfy the 8 membered coordination sphere of Zr.

One interesting adaptation of this chemistry is to reverse the order of the process and form $[^{89}\text{Zr}]\text{DBN}$ and then covalently bind this to the lysine residues of proteins presented on a cell's outer membrane as a novel approach to cell labeling [45]. In the first study applying this method, murine melanoma cells, murine DCs, and human mesenchymal stem cells (hMSCs) were radiolabeled with $[^{89}\text{Zr}]\text{DBN}$ with an efficiency of 30% to 50%. Importantly, this method of labeling did not affect cell viability and their ability to proliferate, however, the most important outcome was no efflux observed for over 7 days post labeling. Radiolabeled hMSCs were

![Fig. 7. The formation reaction and structure of coordinate zirconium-89 tetrakis (8-hydroxyquinolinolinate).](image-url)
intravenously injected into athymic mice and their migration was tracked by PET imaging for 7 days. They were also injected into the myocardium within the ischemic regions of a reperfusion mouse model, being retained in ischemic lesions for the whole imaging period.

Lee et al. performed a similar study – they radiolabeled Jurkat/CAR-T cells with $^{89}$Zr]DBN, reaching 70 – 79% of labeling efficiency and > 95% of cell viability after the procedure. Subsequently, the cells were I.V. injected into mice bearing Raji and K562 cell-tumors, inoculated on the left and right flanks. The mice were PET imaged for 7 days post-injection, revealing that the CAR-T cells progressively migrated from the lungs and trafficked mainly in the liver and in part the spleen. However, an unexpected result was, that cell targeting to the tumors was not observed on PET scans [142]. The radiolabeling of human cardiopoietic stem cells (CPs) using this radiotracer was also successfully performed [143].

This is the only one known radiolabel that does not exhibit significant leaking out of the cells and thus indicates a high potential and wide use in future studies. However, our research results suggest that lymphocytes and macrophages labeled with $^{89}$Zr]DBN may non-specifically create in vivo focal shaped clusters in murine lungs, which may lead to false-positive results in PET studies concerning cell targeting to pathological lesions, such as lung tumors (Fig. 9).

$^{89}$Zr can also be applied in the form of chitosan-conjugate. Chitosan is a biocompatible copolymer of glucosamine and N-acetylglucosamine which can chelate metal ions. This nanoparticle can be incorporated through phagocytosis, therefore the phagocytic capacity of treated cells is essential. Nevertheless, Fairclough et al. performed the labeling of the blood-derived leukocyte fraction, reaching an efficiency of 82.7% after 10 min of incubation, however, continuous, gradual efflux was observed and it reached 53.3% after 2 h [144]. Another method of labeling with $^{89}$Zr harnessing phagocytosis is the treatment of cells with $^{89}$Zr]dextran nanoparticles. Wilks et al. introduced a few reports concerning PET tracking of $^{89}$Zr]dextran-labeled B lymphocytes [145] and T lymphocytes [146,147] in murine models.

Other radiotracers in direct PET imaging. An unusual approach to cell tracking was presented by Pham et al. They introduced a dual PET and fluorescent labeling reagent, $^{124}$IFIT-(PhS)$_2$Mal, with an excellent radiochemical yield and confirmed cell conjugation. $^{124}$IFIT-(PhS)$_2$Mal effectively radiolabeled different cell lines via
their membrane thiols with 22%–62% labeling efficiency with extended radiotracer retention. Due to its fluorescent characteristics, the cell membrane localization of \([^{124}\text{I}]\text{FIT-(PhS)}_2\)Mal was proved by confocal fluorescence microscopy. Prolonged monitoring of the in vivo distribution of \([^{124}\text{I}]\text{FIT-(PhS)}_2\)Mal-labeled Jurkat cells showed that it can be monitored with PET for over 7 days [46]. The same radionuclide is also applied as a conjugate with deoxuryridine ([\(^{124}\text{I}]\text{dU})]. The cell penetration of uridine is based on the principle of transporter uptake – via the concentrative nucleoside transporters (CNT1) [148] and it is incorporated into DNA [149,150]. Although the conjugates of deoxuryridine with various radioisotopes have been used in diagnostics for a long time, they have been mainly used for cancer detection due to their high uptake by the proliferating cells [151]. However, there was an approach in which OVA-specific CD8+ T cells were in vitro radiolabeled with \([^{124}\text{I}]\text{dU}). Because the results showed a distinctive accumulation of injected radiolabeled T cells in B16-OVA-cell melanoma tumors of C57BL6 mice, it was confirmed that this method is effective for the labeling and long-term tracking of T cells [36]. Jung et al. reported the feasibility of a technique termed “CellGPS,” which allows a single radiolabeled cell to be tracked in vivo using PET imaging. Mesoporous silica nanoparticles (MSNs) concentrating high amounts of \([^{68}\text{Ga}]) were loaded into MDA-MB-231 breast cancer cells. Subsequently, an isolated single cell was i.v. administered into an athymic nude mouse. Using PET, it was possible to detect and visualize that single cell. As expected, the arrest of the cell was eventually observed in the lungs [152]. \([^{68}\text{Ga}]) was also used in connection with oxine ([\(^{68}\text{Ga}])oxinate\text{)} to radiolabel and track CAR-T lymphocytes in NZB mice, however, their targeting to CD19-K562-uc and Raji tumors was slow and no significant accumulation was reported. The authors claim, that although \([^{68}\text{Ga}]) allows performing shorter studying compared to \([^{90}\text{Zr}]), it has a better safety profile what suggests, that it could be safely translated into human studies [153].

3.1.3. Tracking of immune cells with radiolabeled antibodies – SPECT and PET

Another interesting approach of nuclear imaging is cell labeling with radionuclide-conjugated antibodies. In contradicition with the direct cell labeling methods, when tracking cells via this strategy the radioisotopes must be tightly bound to the targeting antibody, particularly if the antibody targets a non-internalizing cell surface receptor, as any released radiometal will no longer be cell-associated. As a result, different chemical strategies are required from the direct cell labeling methods discussed above. Radioisotopes may be connected to antibodies directly (e.g., \([^{99m}\text{Tc}]) and the various iodine radioisotopes) or by bifunctional chelating agents linked to antibodies ([\(^{99m}\text{Tc}]), [\([^{111}\text{In}]), [\([89\text{/90}\text{Y}]), [\([89\text{Zr}]), [\([^{68}\text{Ga}]), [\([^{111}\text{In}]), [\([89\text{/90}\text{Y}]), [\([89\text{Zr}]), [\([^{68}\text{Ga}])\text{oxinate}\text{)}]) to radiolabel and track CAR-T lymphocytes in the lungs [152]. \([^{68}\text{Ga}]) was also used in connection with oxine ([\([^{68}\text{Ga}])oxinate\text{)} to radiolabel and track CAR-T lymphocytes in NZB mice, however, their targeting to CD19-K562-uc and Raji tumors was slow and no significant accumulation was reported. The authors claim, that although \([^{68}\text{Ga}]) allows performing shorter studying compared to \([^{90}\text{Zr}]), it has a better safety profile what suggests, that it could be safely translated into human studies [153].

Radioisotopes may be connected to antibodies directly (e.g., \([^{99m}\text{Tc}]) and the various iodine radioisotopes) or by bifunctional chelating agents linked to antibodies ([\(^{99m}\text{Tc}]), [\([111\text{In}]), [\([89\text{/90}\text{Y}]), [\([89\text{Zr}]), [\([^{68}\text{Ga}])\text{oxinate}\text{)}]) to radiolabel and track CAR-T lymphocytes in the lungs [152]. \([^{68}\text{Ga}]) was also used in connection with oxine ([\([^{68}\text{Ga}])oxinate\text{)} to radiolabel and track CAR-T lymphocytes in NZB mice, however, their targeting to CD19-K562-uc and Raji tumors was slow and no significant accumulation was reported. The authors claim, that although \([^{68}\text{Ga}]) allows performing shorter studying compared to \([^{90}\text{Zr}]), it has a better safety profile what suggests, that it could be safely translated into human studies [153].

A unique aspect of the antibody-based labeling technique is the possibility to label cells in two different ways: in vivo – after intravenous administration of the antibody, and in vitro conditions – before administration of the cells. Although the first method has the drawback of non-specific labeling of body cells that have the same receptor as the cells to be tracked, it is much more commonly applied. First attempts of using radiolabeled antibodies are dated back to the 1950s but the development of imaging methods allowed their effective detection only in the 70s [162]. Radiolabeled therapeutic or imaging antibodies approved by FDA and EMA are as follow:

1) compounds for tumor imaging: [\([111\text{In}])\text{satumomab pendetide (approved in 1992), [\([111\text{In}])\text{capromab pendetide (approved in 1996), [\([99m\text{Tc}])\text{arcitumomab (approved in 1998), [\([99m\text{Tc}])\text{nolofetumomab merpentan (approved in 1996), [\([111\text{In}])\text{gogomab (approved in 1996), [\([99m\text{Tc}])\text{-murine antimelanoma fragments (approved in 1996), [\([99m\text{Tc}])\text{votumumab (approved in 1998), [\([111\text{In}])\text{libitumomab tiuxetan (approved in 2002)) [163,164].

2) compounds for tumor therapy: [\([89\text{Y}])\text{ibritumomab tiuxetan (approved in 2002) [165], [\([131\text{I}])\text{tiyoistumomab (approved in 2003) [166]. In these groups, many compounds may be potentially used in cell radiolabeling and tracking trials.
Table 3  Examples of targets and radioisotopes examined in preclinical and clinical trials.

| Agent | Linked isotope | Target molecule | Target cell | Target pathology (for antibody or radiolabeled cells) | Source |
|-------|----------------|-----------------|-------------|--------------------------------------------------------|--------|
| Visilizumab | $^{99m}$Tc | CD3 | HuT78, human lymphoma (ATCC® TIB-161™) | T-cells – to autoimmune diseases | [167] |
| DAbr1 | $^{177}$Lu | CD4 | CAR-DAbr1 T cells | | [168] |
| Anti-ICO-80 | $^{188}$Re | CD5 | Jurkat, T-lymphoblastic lymphoma (ATCC® TIB-152™) | adenocarcinoma, T-Lymphoblastic lymphoma | [169] |
| rat anti-mouse αCD11b mAb (isotype: IgG2b) | $^{64}$Cu | CD11 | Myeloid-derived suppressor cells (MDSCs) | MDSC - to PyMT breast cancer and B16F10 melanoma. | [170] |
| Rituximab | $^{131}$I | CD20 | n/a | non-Hodgkin's lymphoma | [171,172,173,174,175] |
| Lym-1 | $^{111}$In | n/a | n/a | non-Hodgkin's lymphoma | [176,177,171] |
| Epratuzumab (hLL2) | $^{64}$Cu | CD22 | Ramos, human B-cell lymphoma (ATCC® CRL-1596™) | non-Hodgkin's lymphoma | [171,178,179,180,181] |
| Lintuzumab (HuM195) | $^{213}$Bi | CD13 | n/a | myeloid leukemia | [182,183,184] |
| 9E7.4 | $^{64}$Cu | CD138 | 5 T33 murine multiple myeloma | myeloma | [187] |
| IgG2a k rat anti-mCD138 | $^{[213]}$Bi | 5 T33 murine multiple myeloma | myeloma | | [188] |
| syndecan-1 | $^{111}$In | n/a | multiple myeloma | | [189] |
| J591 | $^{177}$Lu | PSMA | LNCaP human prostate cancer (ATCC® CRL-1740™) | prostate cancer | [190] |
| Cetuximab | $^{89}$Zr | 4431, human squamous cell carcinoma (ATCC® CRL-1555™) | squamous carcinoma | | [192] |
| Trastuzumab | $^{111}$In | HER2 | n/a | breast cancer | [193,194,195] |
| ABY-025 | $^{111}$In | n/a | breast cancer | | [196] |
| ZHER2:342-pep2 | $^{111}$In | SKOV-3, human ovary adenocarcinoma (ATCC® HTB-77™) | ovary ascites adenocarcinoma mammary gland adenocarcinomas | | [197] |
| ZHER2:342 | $^{99m}$Tc | SKOV-3, human ovary adenocarcinoma (ATCC® HTB-77™) | ovarian carcinoma | | [198] |
| cT84.66 | $^{90}$Y | CEA | n/a | colorectal cancer colorectal cancer | [203,204,205] |

Ł. Kiraga, P. Rucharszewska, S. Paisey et al. Coordination Chemistry Reviews 445 (2021) 214008

A novel approach involving the use of antibodies has been proposed by Pham et al. - a dual iodinated-fluorescent reagent for cancer PET imaging and fluorescence-guided surgery has been developed. The A5B7 carcinoembryonic antigen (CEA)-specific reagent was conjugated to $[^{125}I]$-Green. The compound was tested in vivo using the SW1222 xenograft model (CEA-expressing) where it was visualized by both PET/CT and fluorescence imaging. CEA $[^{124}I]$-Green had relatively high tumor uptake (20.21 ± 2.70, 13.31 ± 0.73, and 10.64 ± 1.86% ID/g at 24, 48, and 72 h post intravenous injection, respectively [46].

The examples of radionuclide-conjugated antibodies with their affinity to certain molecular targets and the isotopes that they are conjugated are given in Table 3.

In summary, many types of radionuclides are used in immune cells labeling. It is important to be aware that many molecules combined with the radioisotope to form the radionuclide were not originally designed to track cells, so some of them have significant limitations. Using radionuclides that are taken up by the cells that express the specific receptor, in the case of in vivo efflux of the radionuclide, may lead to the undesirable labeling of other cells of the organism. Some macromolecular radiotracers are characterized by a great capacity for radioisotope particles, what reduces their molar concentration in the organism. Some macromolecular radiotracers are characterized by a high capacity for radioisotope particles, which reduces their molar concentration in vivo and limits their application.

### Table 3 (continued)

| Agent | Linked isotope | Target molecule | Target cell | Target pathology (for antibody or radiolabeled cells) | Source |
|-------|----------------|-----------------|-------------|--------------------------------------------------------|--------|
| A5B7  | $[^{131}I]$    | n/a             | n/a         | gastrointestinal adenocarcinoma                        | [207,208] |
|       | $[^{99mTc}]$   | LS174T, human colorectal adenocarcinoma (ATCC® CRL-1886®) | liver metastases |                          | [208] |
|       | $[^{125}I}$    | SW1222, human colorectal adenocarcinoma |                          |                          | [209] |
| ZEGRF-03115 | $[^{68}Zr}$ $[^{89}Y]$ | EGFR CAL27, human tongue squamous carcinoma (ATCC® CRL-2095®) | head and neck squamous cell cancer |                          | [210] |
| ZEGRF-0555 | $[^{111}In}$ | MUC-1 CaPan1 human pancreatic carcinoma (ATCC® CRL-1555®) | squamous carcinoma |                          | [211] |
| PAM4   | $[^{111}In]$   | MUC-1 CaPan1 human pancreatic carcinoma (ATCC® CRL-1555®) | squamous carcinoma |                          | [211] |
| PR81   | $[^{111}In]$   | MCF7, Human parental breast cancer (ATCC® HTB-22®) | breast cancer |                          | [212] |
|       | $[^{99mTc}]$   | n/a             | n/a         | breast cancer |                          | [213] |
| Anti-ICO-25 | $[^{188}Re}$ | SKOV-3 (ATCC® HTB-77®) | adenocarcinoma; T-Lymphoblastic lymphoma |                          | [169] |
| KJ1-26 | $[^{64}Cu}$   | TCR Th1 cells   | lymphocytes to airway delayed-type hypersensitivity reaction |                          | [116,214] |

### Table 4

| Mechanism of cell labeling | Benefits | Drawbacks | Sample references |
|----------------------------|----------|-----------|-------------------|
| Specific receptor uptake   | • Possibility to label cells in vivo by intravenous administration of antibodies | • Non-specific in vivo labeling of body cells that share a common receptor with target cells | [167,170,214] |
| Endocytosis                | • Quick labeling process, high labeling efficiency | • Only phagocytic cells can be labeled | [144,215,216] |
| Transporter uptake         | • Inexpensive and readily available radiotracer ($[^{18}F]$FDG) | • Usually, high efflux of a radiotracer | [42,43,93,97] |
| Passive diffusion          | • Various radiotracers available, both for SPECT and PET imaging | • Typically rapid elution of a radiotracer | [45,71,77,115,131] |
| Absorption into the cell membrane | • The labeling process does not affect cell viability, phenotype, or migration potential | • Typically low labeling efficiency | [44,45,103,117] |
| Binding to the cell membrane proteins | • No cellular efflux of a radiotracer – stable retention | • In theory, binding of a radiotracer to membrane proteins, has the potential to affect cell functionality | [45,46,99,100,200] |
function. Nevertheless, the correct choice of radioactive agent should depend on the cell type intended to be labeled and the duration of the cell tracking study. The advantages and disadvantages of each direct labeling process are listed in Table 4.

### 3.2. Indirect cell labeling

Indirect labeling with reporters involves the introduction of a reporter gene to the immune cells under *in vitro* conditions before cell transplantation. Alternatively, immune cells isolated from transgenic animals that express a reporter gene of interest can be used [217]. These reporter genes are designed to induce an additional function to the cells to make them uniquely targetable repetitively at any time following cell transplantation. The indirect cell labeling provides several advantages as compared with the direct techniques, including the possibility of longitudinal monitoring of labeled immune cells over their entire lifetime, as well as tracking of proliferating and viable cell populations that express the imaging reporter genes. However, transfection of the reporter genes may be compromised by gene silencing through epigenetic mechanisms such as histone deacetylation or DNA methylation, leading to suppression of the reporter gene expression [218]. Treatment of cells with a DNA methyltransferase inhibitor may overcome this problem [219].

Both viral and non-viral methods have been used for the successful introduction of reporter genes to cells. Viral gene transfer makes use of viruses to introduce the reporter gene into the genome of the target immune cell and does not require any transfection reagents. Nowadays, lentiviruses and retroviruses are most commonly employed for genetic manipulation of immune cells [168,220–223]. Reporter gene transfection with non-viral methods

---

**Table 5**  
List of reporter genes and radiotracers.

| Reporter gene | Reporter probe | PET/ SPECT | Advantages | Disadvantages |
|----------------|----------------|------------|------------|---------------|
| Herpes simplex virus type 1 thymidine kinase (HSV1-tk) and mutants | ^18Fluoro-3-(hydroxymethyl)butyl guanine | PET | lack of the reporter gene in mammalian cells | immunogenic viral protein, evoking immune-dependent recognition and elimination of immune cells transduced with HSV1-tk |
| | | | relatively high sensitivity | induced expression of the reporter gene may change cell biological function |
| | | | dual activity as a molecular imaging gene and a suicide gene | reporter probes do not cross the blood-brain barrier (BBB) |
| | | | enzymatic signal amplification through phosphorylation and trapping of a specific radiolabeled probe | deiodination of the radio-iodine labeled probes |
| E. coli dihydrofolate reductase (eDHR) | ^18Fluoro-3-(hydroxymethyl)butyl guanine | PET | lack of the reporter gene in mammalian cells | immunogenic bacterial protein, potentially evoking immune-dependent recognition and elimination of immune cells transduced with eDHR |
| | | | high sensitivity | defluorination of the radiotracer → notable radioactivity in bones |
| | | | enzymatic signal amplification through phosphorylation and trapping of a specific radiolabeled probe | |
| Varicella-Zoster Virus thymidine kinase (VZV-tk) | ^18FFluoro-3-(hydroxymethyl)butyl guanine | PET | lack of the reporter gene in mammalian cells | immunogenic viral protein, potentially evoking immune-dependent recognition and elimination of immune cells transduced with VZV-tk |
| | | | relatively high sensitivity | reporter probe does not cross the BBB |
| | | | enzymatic signal amplification through phosphorylation and trapping of a specific radiolabeled probe | |
| Human mitochondrial thymidine kinase (hMTK2) and mutants | ^18Fluoro-3-(hydroxymethyl)butyl guanine | PET | a human protein → substantially reduced risk of inducing an immune response against cells transduced with this reporter gene | reporter probes do not cross the BBB |
| | | | dual activity as a molecular imaging gene and a suicide gene | high activity in organs engaged in clearance |
| | | | enzymatic signal amplification through phosphorylation and trapping of a specific radiolabeled probe | deiodination of the radio-iodine labeled probes |
| | | | | possible disturbance of cell function |

---

**Fig. 10.** Diagram of different indirect cell labeling processes, with examples of radiotracers and reporter genes. SPECT radiotracers are listed in red font and PET radiotracers in black font.
Table 5 (continued)

| Reporter gene | Reporter probe | PET/ SPECT | Advantages | Disadvantages |
|---------------|----------------|------------|------------|---------------|
| **Human deoxyxytidine kinase (hdCK)** double and triple mutants | $[^{18}F]$FEAU – 2-[^{18}F]fluoro-5-ethyl-1-beta-D-arabinofuranosylacil | PET | • a human protein → substantially reduced risk of inducing an immune response against cells transduced with this reporter gene | • reporter probe does not cross the BBB • potential modification of cell characteristics like all other reporter genes |
| **Human dopamine receptor type 2 (D2R) and its mutant** | $[^{18}F]$FESP – 3-(2-[^{18}F]-fluoroethyl)-siperone, $[^{11}C]RAC – [^{11}C]aclopride | PET/PET | • a human protein → substantially reduced risk of inducing an immune response against cells transduced with this reporter gene | • high background in pituitary and striatum due to D2R expression in these tissues • slow clearance of $[^{18}F]$FESP |
| **Human somatostatin receptor subtype 2 (hSSTR2)** | $[^{11}In]$/pentetreotide, $[^{106}Ga]$/DOTATATE – $[^{109}Ga]$1,4,7,10-tetraazaacyclododecane-1,4,7,10-tetraaetatic acid-(Tyr3)-octreotate, $[^{10}F]$DOTATOC – $[^{109}Ga]$1,4,7,10-tetraazaacyclododecane-1,4,7,10-tetraaetatic acid-(Phel-Tyr3)-octreotide | SPECT/PET | • a human protein → substantially reduced risk of inducing an immune response against cells transduced with this reporter gene | • binding of somatostatin to hSSTR2 may cause cell signaling → transgene overexpression may perturb cell function • hSSTR2 expressed on some tumors and tissues |
| **Human estrogen receptor z ligand binding domain (hERL)** | $[^{18}F]$FES – 16α-[^{18}F]-fluoro-17β-estradiol | PET | • a human protein → substantially reduced risk of inducing an immune response against cells transduced with this reporter gene | • tissue background due to expression in uterus, ovaries, mammary gland and breast cancer cells |
| **Engineered DOTA antibody reporter 1 (DAbR1)** | $[^{17}Lu]$ABD – $[^{17}Lu]$-5-(2-(4-acrylamidobenzyl)-DOTA, $[^{90}Tc]$/JABB – $[^{90}Tc]$(5-2-(4-acrylamidobenzyl)-DOTA | SPECT/PET | • humanized molecular imaging reporter gene | • possibly immunogenic protein • $[^{90}Tc]$ is not a good PET radioisotope |
| **Cannabinoid receptor type 2 (CB2R) and its mutant** | $[^{11}C]$/GW405833 – $[^{11}C]$/-1-(2,3-Dichlorobenzoyl)-5-methoxy-2-methyl-3-[2-(4-morpholinyl)ethyl]-1H-indole | PET | • a human protein → substantially reduced risk of inducing an immune response against cells transduced with this reporter gene | • tissue background due to expression in spleen, cells of the immune system and brain under inflammatory conditions |
| **Human sodium iodide symporter (hNIS)** | $[^{124}I]$MBG – $[^{124}I]$/metaiodobenzyl guanidine, $[^{123}I]$MBG – $[^{123}I]$/metaiodobenzylguanidine | SPECT/PET | • a human protein → substantially reduced risk of inducing an immune response against cells transduced with this reporter gene | • tissue background due to hNIS expression in normal tissues, such as thyroid, stomach, salivary glands, mammary glands • radioprobes can efflux since they are not trapped in cells → short imaging window |
| **Human noradrenaline transporter (hNET)** | $[^{123}I]$MBG – $[^{123}I]$-metaiodobenzyl-guanidine, $[^{124}I]$MBG – $[^{124}I]$metaiodobenzylguanidine, $[^{123}I]$MBG – $[^{123}I]$metafluorobenzylguanidine | SPECT/PET | • a human protein → substantially reduced risk of inducing an immune response against cells transduced with this reporter gene | • high tissue background due to hNET expression in many normal tissues • induced expression of this transgene may affect cell biological function |
involves the use of electroporation, polymers, chemical vectors, nanoparticles, or cationic transfection agents [224]. Gene transfer with non-viral techniques is rarely used for genetic manipulation of immune cells. In general, three major groups of imaging reporter genes can be distinguished [10,225,226]:

1) enzymes - resulting in metabolic entrapment of the radiotracer inside the cell,
2) transmembrane receptors - binding radiolabeled probes,
3) transporters - actively pumping the radiotracer into the cytoplasm.

Different radiotracers grouped by the mechanism of indirect cell labeling are presented in Fig. 10.

Many imaging reporter genes exist for immune cell tracking, such as non-human reporter genes (herpes simplex virus type 1 thymidine kinase (HSV1-tk), E. coli dihydrofolate reductase (eDHFR) and Varicella-Zoster Virus thymidine kinase (VZV-tk)) as well as human reporter genes, including human deoxycytidine kinase (hdCK), human mitochondrial thymidine kinase (hmTK2), human dopamine receptor type 2 (D2R), human somatostatin receptor subtype 2 (hSTR2), human estrogen receptor α ligand binding domain (hERL), human norepinephrine transporter (hNET), and human sodium-iodide symporter (hNIS) [12,13,16,226].

Table 5 lists the imaging reporter gene/radioprobe systems that have so far been studied and provides advantages and disadvantages of using each reporter system for immune cell tracking. One of the most broadly evaluated imaging reporter enzymes for nuclear imaging is HSV1-TK and its many variants, which mediate the uptake of substrates tagged with radioisotopes suitable for SPECT or PET analysis. Radioactively labeled nucleoside analog substrates are phosphorylated by thymidine kinases. The examples are 2-[18F]fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil ([18F]F AUA), 2'-fluoro-2'-deoxy-1-beta-D-arabinofuranosyl-5-[124I]iodouracil ([124I]FIAU), 9-[(4-[18F] fluoro-3-hydroxymethylbutyl) guanine ([18F]FHBG), providing them with a negative charge, which results in the entrapment of these substrates inside the cell [227,228]. Several studies have shown that tumor-infiltrating lymphocytes can be successfully tracked with the HSV1-TK reporter enzyme in mice [229,230] or in humans [231]. However, immune cells expressing HSV1-TK may evoke potential immune reactions due to the viral origin of this reporter enzyme. Similar immune reactions are expected to occur in response to cells expressing other non-human reporter genes, such as eDHFR and VZV-tk. Immunogenicity against non-human reporter proteins may lead to major problems in cell kinetics monitoring studies due to eradication of cells expressing the reporter gene. Thus, to overcome this shortcoming and to reduce immunogenicity, various human-derived reporter genes have been developed. However, the exploitation of such endogenous human genes for in vivo cell tracking has three potential problems: first, the reporter probes may also accumulate in cells expressing the endogenous gene causing high tissue background; second, the imaging reporter gene may act like the endogenous gene and thus affect the functioning of the cell in which it is expressed; third, there is still limited knowledge concerning the immunogenicity of these human imaging reporter genes. To overcome some of these problems mutations have been introduced in some of these genes to either eliminate their function [232] or to increase their detection sensitivity with a specific reporter probe [233]. Two human-derived, enzyme-based reporter genes, hmTK2 and hdCK, represent attractive nuclear imaging reporter genes for live cell tracking imaged with pyrimidine-based radiotracers [229]. The second group of reporter genes used for tracking live immune cells with nuclear imaging are receptors, including human dopamine receptor type 2 (D2R) and hSTR2, which bind their radiotracers on the outside of the cell. The hSTR2 is a non-immunogenic protein that has been used as an imaging reporter receptor for immune cell tracking using its ligand [99mTc] DOTATOC [234,235]. Selective radiotracer import through transporters, such as hNIS and hNET, is another method for live immune cell tracking with nuclear imaging. hNIS is a glycosylated ion channel present on the cell membrane and is expressed in salivary and thyroid glands, but also in the stomach, where it transports iodine to the cells for sodium exchange. Its expression in target immune cells enables the receptor-dependent uptake of numerous radiotracers, such as radiodiode ([123I], [124I] and [131I]) and [99mTc]- pertechnetate ([99mTcO4−]). The major advantage of using hNIS for immune cell tracking is the fact that some radiolabeled probes taken up by this receptor, such as [99mTcO4−], are already used for PET and SPECT imaging in the clinic [236,237]. Additionally, hNIS does not evoke an immune response, because of its human origin, and thus may be potentially used in clinical settings. hNET is another non-immunogenic reporter gene encoding a transmembrane protein that transports clinically approved analogs of noradrenaline, such as metaiodobenzylguanidine (MIBG) or metafluorobenzylguanidine (MFPG) across the cell membrane. MIBG can be radiolabeled with [123I] and [131I] for planar gamma scintigraphy and SPECT imaging, and with [124I] for PET imaging [238,239]. It was also possible to synthesize a complex of different guanidines with 11C as an indirect PET radiotracer [240]. A recently developed group of reporters used for indirect immune cell labeling are genetically introduced radiotracer–detectable surface tags. One such example is the DOTA antibody reporter 1 (DAbR1) that is a fusion of a single-chain fragment of a Y-DOTA. Ab 2D12/S-G54C and transmembrane domain of human T-cell. This cell surface tag may be visualized with PET and SPECT imaging following irreversible coupling of lanthanoid (S)-2-(4-acylamidobenzyl)-DOTA (AABD) radiolabeled with yttrium-86-[86Y] or lutetium-177-[177Lu], respectively [168].

3.2.1. Tracking of indirectly labeled immune cells with SPECT imaging

As described earlier, indirect cell labeling requires genetic modification of the cells for the expression of reporter genes encoding enzymes, receptors, or importers, that induce accumulation of the radiolabeled probe inside the cell. Unlike direct labeling methods, this strategy enables longitudinal immune cell tracking following cell administration. Various reporters, including hNIS, hNET, and SSTR2 have been tested for adoptive cell therapy monitoring with SPECT imaging. In a preclinical study by Emami-Shahri et al., the PSMA-specific P28; CAR-T cells were genetically modified to co-express hNIS, and then administered to mice with PSMA-expressing tumors [221]. Following the adoptive transfer, repetitive imaging with SPECT was employed to track [99mTcO4−] uptake via the hNIS transporter in the CAR-T cells for up to 21 days. Tumor infiltration by T cells shown with SPECT imaging was confirmed by immunochemistry analysis of tumor tissue. This study showed that adoptive T cells expressing hNIS reporter gene could be tracked in vivo longitudinally with nuclear imaging, enabling analysis of the correlation between tumor infiltration by CAR-T cells and tumor growth. In vivo monitoring of Tregs seems to be of great importance for checking the biodistribution of these immune suppressive cells in patients with autoimmune disorders or after organ transplantation. To track the migration of Tregs in vivo, autologous Tregs were expanded under ex vivo conditions and then genetically modified with the hNIS reporter system for the [99mTc] radiotracer detection by SPECT/CT imaging [241]. Imaging analysis revealed increased infiltration of the spleen by Tregs as compared with other organs. This preclinical study demonstrated that adoptively transferred Tregs can be tracked in vivo in a time-dependent manner with SPECT/CT imaging, as this approach does not affect Treg function and viability. Future research will show whether this approach
may be exploited in the context of inflammatory or autoimmune diseases. hNET, which binds and takes up clinically approved radiotracers such as MIBG or MFBG, is another reporter gene option for indirect immune cell tracking with SPECT. In a study by Doubrovin et al. human EBV-specific T lymphocytes were transduced to express hNET, and then injected intratumorally into EBV tumours. After intravenous administration of radiotracers specific for the hNET reporter probe ([123I]MIBG for SPECT or [124I]MIBG for PET), as little as 10⁴ hNET-expression T cells injected intratumorally were detected by SPECT or PET imaging. For longitudinal studies, hNET-expressing EBV-specific T cells were administered intravenously and then tracked for accumulation in EBV tumours for up to 28 days with SPECT or PET imaging. This study showed that the hNET reporter system is safe and non-immunogenic, and thus potentially may be used for longitudinal in vivo imaging of genetically modified immune cells in humans [238]. In another study, Moroz et al. directly compared various reporter systems for in vivo T cell detection. To this end, mice were injected subcutaneously with various numbers of T cells transduced with one of the following reporter genes hNET, hNIS, hDCKDM, and HSV-tk, followed by SPECT or PET detection using various radiotracers [242]. SPECT imaging with hNET and [123I]MIBG tracer was the least effective as it required more than 10⁷ T cells to generate a signal. The highest sensitivity, allowing for detection of only 40 000 injected cells, was observed for hNET and [124I]MFBG radiotracer among various reporter gene-radiotracer combinations for PET that were evaluated.

Analogous to the reporter genes mentioned previously, efforts have been made to transduce immune cells for the expression of a surface tag-detected with a radiotracer for nuclear imaging. One such example is DABR1 marker, which is made up of a single-chain fragment of the anti-lanthanoid-DOTA 2D12.5/G54C antibody linked to the CD4 transmembrane domain, which attaches covalently to AABD tracer. This tag has been recently successfully expressed in CAR-T cells and primary human T cells [168], and these cells not only showed efficient radiotracer uptake in vitro but also, could be tracked with AABD tracer labeled with [18F] (PET) or [125I] (SPECT) upon intravenous administration to mice. Nuclear imaging analysis showing the highest radiotracer activity in the areas infiltrated by CAR-DABR10-modified T cells was additionally corroborated with autoradiography and CD3 IHC staining.

3.2.2. Tracking of indirectly labeled immune cells with PET imaging

PET imaging has been successfully employed to track indirectly labeled immune cells with high sensitivity both in preclinical and clinical settings. Enzyme-mediated substrate alteration is commonly used for specific radiotracer entrapment in immune cells expressing enzymatic reporter genes. Up till now, various reporter enzymes and their substrates have been investigated in the context of in vivo immune cell tracking. The most extensively evaluated PET reporter gene, as mentioned in a previous paragraph, is HSV1-tk with its product HSV1-TK. Substrates of this enzyme are pyrimidine nucleoside analogs (e.g., FIAU: 5-iodo-2-fluoro-2-deoxy-1-D-arabinofuranosyluracil; FEAU: 2-fluoro-2-deoxyarabino-nofuranosyl-5-ethyluracil), or acyclouracines derivatives (e.g., FPCV: fluoropenclovir; FHBG: 9-[4-fluoro-3-[(hydroxymethyl) butyl] guanine], which upon labeling with 18F or 125I can be used for in vivo PET imaging, however radiolabeled FHBG ([124I]FHBG) is more sensitive than the other radiotracers [243]. This reporter system has been employed to track human T cells in a mouse tumor model. Koelne et al. transduced Epstein-Barr virus (EBV)-specific human T cells with the HSV1-TK reporter enzyme and observed with PET imaging that following administration of [124I] FIAU or [124I]FIAU radiotracers, adoptively transferred HSV1-TK-expressing T cells located to EBV-positive tumor xenografts in mice [229]. Importantly, exposure of transduced T cells to the radiotracer did not affect their cytolytic activity. In another study, PET imaging of T cells upon [124I]FHBG radiotracer administration allowed quantification of their homing during inflammation [244]. Clinical use of this technology is reported in the study by Yaghoubi et al. [230,245]. Using PET, Keu et al. studied glioblastoma homing of CD8+ CTLs expressing CAR IL-13, and HSV1-TK reporter enzyme that facilitated [124I]FHBG uptake. The analysis of [124I] FHBG signal on PET images performed before and after CTL injection was very useful to show CTLs trafficking, survival, and proliferation [231].

The viral origin of the HSV1-tk reporter gene is its major limitation, as it can evoke potential immune reactions against cells carrying this gene. This limitation has been overcome by the generation of different mutants of human dCK, which selectively phosphorylate fluorinated thymidine analogs. Human prostate-specific membrane antigen (PSMA)-specific CAR-T cells have been successfully transduced with the human dCK double mutant (dCKDM) reporter gene before transplantation and then visualized in PSMA-positive prostate metastases in the lungs with [124I]FIAU radiotracer and PET imaging within 6 h after T cell administration [233]. In another study, tumor infiltration by T cells co-expressing the triple mutant hdCK3mut with a melanoma antigen-specific T cell receptor was studied with [124I]FIAU-MAU (1-2-deoxy-2-fluoro-β-L-arabinofuranosyl) thymidine) radiotracer and PET imaging [246]. PET analysis showed that human leukocyte antigen (HLA)-matched tumors had higher T cell-associated radioisotope signal as compared with HLA-mismatched tumors. Importantly, the expression of various mutants of human dCK did not evoke any changes in behavior and viability of transduced cells, supporting the utility of monitoring adoptive cell transplantation with human dCK mutants and PET reporter imaging.

Selective radiotracer import via exporters encoded by reporter genes such as hNIS, hNET, and SSTR2 is another common approach for tracking live immune cells with PET imaging. Ahn et al. studied trafficking of bone marrow-derived DC (BMDC) transduced with luciferase/hNIS reporters for bioluminescence imaging (BLI) and PET imaging using [124I] as a radiotracer, respectively [247]. After 7 days of BMDC injection into a footpad, both imaging modalities showed enhanced signal in the draining lymph nodes, suggesting DC trafficking. In another study, the lymph node homing of the murine DC line DC2.4, transduced with the same luciferase/hNIS reporter system, was successfully visualized using BLI and PET/CT imaging with another probe for hNIS reporter gene, [18F]-tetrafluoroborate ([18F]TFOB), in live mice [237], supporting the use of hNIS/[18F]TFOB reporter system in conjunction with PET imaging for monitoring immune cells in live animals. This approach has also found application in autologous human CAR-T cells tracking. Volpe et al. developed a novel platform to induce co-expression of both CAR and hNIS-RFP – a fused radionuclide-fluorescence reporter gene. The introduction of this unique set of genes induces human T lymphocytes to express CAR, red fluorescent protein, and transporter for [18F]TFOB and [90Y]TcO4, allowing the cells to be detected by fluorescence imaging, PET, and SPECT. The cell tracking to triple negative breast cancer (established by orthotopic human MDA-MB-436 and MDA-MB-231 cells inoculation into NSG mice) was evaluated. Interestingly, significant retention of CAR-T cells was observed only in MDA-MB-436 tumors. It appeared that CAR-T targeting to tumors was inversely correlated with immune checkpoint expression in triple negative breast cancer (TNBC) models [248].

SSTR2 is another human reporter gene that has been successfully employed to monitor in a quantitative and time-dependent manner the biodistribution and antitumor effects of CAR-T cells using the [68Ga]-labeled somatostatin analog ([68Ga]DOTA), and PET reporter imaging in a preclinical mouse tumor model.
This study showed that low numbers of CAR-T cells could be visualized with high sensitivity and specificity, and [68Ga]DOTATOC uptake in the tumor correlated with tumor development. This PET analysis was successfully validated by the immunohistochemistry analysis of tumor tissues showing the correlation between the uptake of [68Ga]DOTATOC and percent of CAR-T cell homing into the tumor.

A very novel approach to indirect cell labeling was implemented by Minn et al. Taking advantage of the fact that PSMA has limited expression in human tissue almost only to the prostate, they created transgenic human blood-derived CD19-tPSMA\textsuperscript{N\textsubscript{D3}} CAR-T cells. Prostate-specific membrane antigen (PSMA) expressed on the cell surface of those cells was exploited as a target for [18F]DCFPyL, which acted as an indirect radiolabel. The experimental model was NSG mice with S.C. inoculated Nalm6-eGFP-fluc cell tumors. On the 12th-day post CAR-T cells I.V. injection, a clear PET signal at the tumor side was detected, which indicated that most of the injected cells infiltrated tumor tissue [249].

The aforementioned labeling methods are powerful tools for monitoring immune cells in vivo, although they all have both advantages and disadvantages. The application of genetically modified cells in patients can lead to severe regulatory complications and may increase the cost of diagnostics. On the other hand, it is easier to perform direct labeling from a technical standpoint - the method does not require an in vitro labeling step - instead, the radiolabel can be administered to the patient intravenously. Furthermore, the possibility of continuous monitoring of labeled immune cells over their entire lifetime is undoubtedly of great value. Hence, it is of great importance to appropriately match the cell labeling strategy with the purpose of the immune cell tracking study. Importantly, to date, there are no reports that would indicate impaired immune cell function caused by any of these approaches.

4. Cell tracking in clinical practice

Implementation of cell tracking methods in clinical practice still needs to face many regulatory and practical issues. Based on the preclinical data, indirect cell labeling has many advantages over the direct method. The possibility of longer cell tracking, the ability to monitor cell proliferation, and fate are the most important advantages. However, several issues need to be solved.

First of all, the range of available radioisotopes is limited. The development of reporter genes expressed in tracked cells that require already clinically approved and nontoxic radioisotope is an ongoing fast and efficient solution. Otherwise, the search for new labels will need to undergo the whole regulatory path.

Another aspect concerns the genetic engineering of the cells. The development of CAR-T technology gives the possibility to use gene-editing approaches in cell labeling for clinical use. Of course, the use of new vectors needs to face many regulatory issues, increasing cost and logistics of preparation of the cell-based product. However, one solution for that might be the co-delivery of the reporter gene in the same vector as the therapeutic gene [226].

The next aspect that cell labeling methods will face is the need for method tailoring. Different cells and different labels should be employed depending on the type of disease and its location. Different diseases attract different leukocyte populations. This is particularly true in oncology, as cancers are located at different sites, have different features (e.g. ‘cold’ vs. ‘hot’ tumors), and different neighboring tissues that may limit the selection of the proper radioisotope.

The unwanted accumulation of radioactivity in normal immune organs and tissues is also related to the previous comments as isotope carrying cells may certainly be endowed with preferred tropism towards selected tissues, independent of the tumor environment. This aspect is of particular concern in the case of cells carrying long half-life radionuclides.

A specific issue that must also be addressed concerns the stability of labeled cells. In the case of direct methods, the chemical stability of the isotope chelator moiety towards intralysosomal enzymes is an important experimental variable to be considered. In the case of indirect labeling, also the half life of the reporter gene product must be assessed with caution. In fact, most reporter genes, even when fused with long lived protein moieties, may be targeted by the ubiquitin system and degraded at the proteasome intracellular sites. In both cases (direct and indirect), the degradation of the carrier inside the cell will lead ultimately to the leakage of the isotope outside the cell. As the last issue, the viability of the whole cell itself must be considered given possible intrinsic toxicity of the isotope label at a high concentration within the tracked cell.

Last but not least, before the cell labeling will be a routinely implemented method into clinical practice, the precise biological mechanisms of cell labeling and its effect on the cells and the whole organisms need to be studied [250].

Therefore, from a regulatory and technical point of view, direct cell labeling methods appear to be the most convenient ones in terms of costs and time and also the safest ones in clinical routine, especially when used for short-term cell tracking for diagnostic purposes.

5. Summary

In recent years nuclear imaging methods have been established for noninvasive and real-time monitoring of the long-term distribution and viability of adoptively transferred immune cells, including T cells, B cells, DCs, macrophages, and NK cells, both in preclinical and clinical settings. The most important studies, which were cited in this manuscript, are listed and summarized in Supplementary Table 1. Tracking of immune cells with nuclear imaging has been used for a long time in routine medical practice for diagnostic purposes in infections and inflammatory processes. Radioisotope-based imaging provides numerous advantages in basic research and clinical practice as compared with other molecular imaging modalities. Nuclear imaging modalities are exceptionally sensitive allowing for the use of sub-pharmacological amounts of radiotracers for cell labeling, that will not evoke any biological reactions. Furthermore, these imaging modalities provide quantitative analysis, e.g. in vivo concentration of the radiotracer in the tissue region of interest. Besides, the development of multimodal cameras (PET/CT, SPECT/CT, PET/MRI) provides detailed molecular information at both functional and anatomical levels, which overcomes the major shortcoming of nuclear imaging that is the absence of anatomical information. Finally, a great number of novel radiotracers for direct and indirect labeling strategies are being developed, and the growing availability of radiopharmaceuticals and imaging cameras will eventually broaden our understanding of immunological processes in living organisms. The summary of the currently used radiotracers in cell tracking studies containing valuable information concerning their dosage, normal systemic distributions and safety is provided in Table 6.

Immune cell labeling for nuclear imaging, which is essential for live-cell tracking, may be accomplished with direct or indirect labeling techniques. Direct labeling of immune cells, which is performed under in vitro conditions with radiotracers before cell transplantation, gives specific images of low cell numbers with no need for genetic manipulation. Hence, immune cell labeling with direct methods using radiotracers approved for clinical use may be potentially translated into the clinic. Indirect labeling, which involves the introduction of a reporter gene (e.g., HSV-TK, hNIS, hNET, and SSTR2) into host cells provides the highest sensitivity and can be employed for longitudinal studies of immune cell
The summary of the radiotracers used for immune cell tracking and data concerning their dosages, safety and systemic distribution.

| Radiotracer | Cell type + radioactivity of dosage (administered in vitro in direct and in vivo in indirect cell labeling) | Safety; reported side effects | Data on systemic distribution; absorption coefficient in normal organs |
|-------------|------------------------------------------------------------------------------------------------|-----------------------------|------------------------------------------------------------------|
| passive diffusion | • DB8'Tc lymphocytes (CTLs) with affinity to the Melan-A melanoma antigen. Cells were resuspended in 1 ml of [111In]oxine with a total radioactivity of 2 μCi/10^6 T cells [75] • γδ T cells labeled with the standard nuclear pharmacy [111In]-oxine method at 5 pCi/cell [60] • allogenic NK cells [62] • umbilical cord blood hematopoietic progenitor cells (UCB-NK cells) 2 MBq of [111In]oxinate was added per 10^6 cells [64] • monocyte-derived nonmatured DC (nmDCs) or matured DC (mDCs) – from 0.7 MBq to 20 MBq [82] | • it is reported that [111In] is secreted in human milk following administration [251] • sensitivity reactions (urticaria) have been reported [251] • recent studies have found no evidence of carcinogenicity in either rats or mice given oxyquinoline in feed at concentrations of 1500 or 3000 ppm for 103 weeks [251] • it has been denoted, that human lymphocytes labeled with recommended concentrations of [111In]oxine showed chromosome aberrations consisting of gaps, breaks and exchanges that appear to be radiation induced [252] | • administration of [111In]oxine is followed by excessive accumulation of radioactivity in kidneys [253] • [111In]oxine bioaccumulation is observed mainly in liver, spleen, kidneys, bone marrow, stomach, intestine, lungs and muscles [254] |
| [111In]tropolone | • 1.99 – 7.38 x 10^8 human blood-derived WBC + 400 μCi (containing 25 ug tropolone and 37 MBq [111In] per ml) [67] • human blood derived granulocytes = 500–600 μCi [68] • 5 x 10^8 human blood-derived γδ T cells + 1 or 10–15 MBq [69] • 5 x 10^8 human blood-derived γδ T cells + 10–15 MBq [69] | • extensive studies of cellular viability of cells using [111In]tropolone do not report any adverse effects [255] • no adverse effects on animals or patients have been denoted | • distribution studies in animals with tropolone demonstrated an increased concentration in tissues of high lipid content when compared with appropriate controls [256] |
| [99mTc]HMPAO | • radiolabeling of the human mononuclear cell fraction derived from 120 ml whole blood + 280 MBq [99mTcHMPAO] [38] • autologous granulocytes and eosinophils were incubated with up to 700 MBq of [99mTcHMPAO] [81] • autologous venous blood eosinophils (mean, 120 MBq; range, 46–199 MBq injected/subject) [83] • C57+B6 T cells were directly radiolabelled with ~5 MBq of [99mTcHMPAO] [86] • a part of both mature and immature DCs (about 9 x 10^6) + 20 mCi [87] | • non-specific activity is oftentimes seen in kidneys, thus causing false-positive results [49] • a very few cases of mild hypersensitivity evidenced by the development of an urticarial erythematous rash have been reported following direct intravenous injection; no serious adverse effects on animals or patients have been denoted [257] | • uptake in the brain reaches a maximum of 3.5–7.0% of the injected dose within one minute of injection; about 20% of the injected dose is removed by the liver immediately after injection and excreted through the hepatobiliary system; about 40% of the injected dose is excreted through the kidneys and urine over the 48 h after injection resulting in a reduction in general muscle and soft tissue background [257] |
| [99mTc]SnF2 | • human blood leukocytes (585 MBq, labeling efficiency 36% – 99.7%) [89] | • no adverse effects on cells nor patients have been denoted | • high uptake in the liver of healthy rats (85.7% of injected dosage), lower in lungs (3.13) and spleen (7.65) [258] |
| transporter uptake | • 6.6 x 10^6 – 1.5 x 10^7 human DCs per sample + 84.7 MBq [65] • mixed leukocyte fraction from human blood + 3.7–74 mBq [93] • autologous leukocytes + 314.5–555 MBq (8.5–15 mCi) [96] | • [18F]FDG for imaging requires the patient to fast before injection and in the case of diabetic patients, blood glucose levels should be monitored before the administration of [18F]FDG [259] • the amounts of [18F]FDG excreted in breastmilk are below the level of concern for the breastfed infant and most international radiation safety organizations state that no interruption of breastfeeding is necessary [260] • overdoses of [18F]FDG injection have not been reported [261] | • excessive and oftentimes non-specific [18F]FDG uptake has been observed in many organs such as the heart, brain, and muscle, and kidneys [49] • [18F]FDG accumulates mainly in the bladder, heart, pancreas, spleen, lungs, and kidneys [261] |
| [124I]dU | • OVA-specific CD8 + T cells (no data available on the cell number and radioactivity of the compound) [36] | • no adverse effects on animals or patients have been denoted • however, it has been known, that the precocin - deoxyuridine exhibits dose dependent antigen toxicity leading to perturbation of chromatine [149] | • in humans, marked accumulation of radioisotopes in the thyroid, salivary glands, intestines, stomach, esophagus and along with elevated uptake in the bone marrow and liver and overall moderate enhancement in the mediastinum and throughout the abdominal cavity [150] |

(continued on next page)
| Radiotracer | Cell type + radioactivity of dosage (administered in vitro in direct and in vivo in indirect cell labeling) | Safety; reported side effects | Data on systemic distribution; absorption coefficient in normal organs |
|-------------|-------------------------------------------------------------------------------------------------|-----------------------------|---------------------------------------------------------------------|
| **passive diffusion** |  |  |  |
| $[^{64}\text{Cu}]$PTSM | • murine splenic lymphocytes ($2.8 \times 10^7$ cells) were labeled with 72 $\mu$Ci of $[^{64}\text{Cu}]$-PTSM in 1 ml of medium [39]  
• $1 \times 10^6$ murine OVA Th1 lymphocytes; 0.7–2.2 MBq of $[^{64}\text{Cu}]$PTSM [116] | • no adverse effects on animals or patients have been denoted  
• excellent uptake in the brain, liver, and heart after intravenous injection [262]  
• no data on bioaccumulation of the radiotracer administered to a healthy organism |  |
| $[^{89}\text{Zr}]$chitosan | | |  |
| $[^{89}\text{Zr}]$dextran | | |  |
| $[^{89}\text{Zr}]$DBN | • human white blood cell fraction (derived from 40 ml venous blood) was incubated in saline with 74–185 MBq $[^{89}\text{Zr}]$dextran [117] | • no adverse effects on cells, animals or patients have been denoted  
• no data on bioaccumulation of the radiotracer |  |
| $[^{68}\text{Ga}]$oxinate3 | | |  |
| $[^{64}\text{Cu}]$tropolone | • CAR-T lymphocytes in NSG mice; $1 \times 10^6$ CAR-T cells were incubated with 1.11 MBq $[^{64}\text{Cu}]$tropolone; solution [153] | • no adverse effects on animals or patients have been denoted  
• most likely - analogous to other oxine-based radiotracers; in rat, fast accumulation of the radiotracer in the liver (SUV 6.8) [263] |  |
| absorption into the cell membrane |  |  |  |
| $[^{18}\text{F}]$HFB | • human circulating progenitor cells (CPC); different dose ranges of $[^{18}\text{F}]$HFB (0.4–0.6, 1.5–2.5, or 5.0–7.0 mCi) [103] | • no adverse effects on animals or patients have been denoted  
• the labeling efficiency was evaluated so far only in rodent mesenchymal stem cells - after 30 min it reached 25% and cell viability was found to be > 90%; furthermore, there was a retention of radiotracer in the cells > 90% over 4 h [44]  
• predominant uptake of free $[^{18}\text{F}]$HFB is observed in the liver [102] |  |
| binding to the cell membrane proteins |  |  |  |
| $[^{18}\text{F}]$FBEM | • $1.3 \times 10^7$ splenic T lymphocytes from C57Bl/6 mice + 33 MBq [99] | • no adverse effects on animals or patients have been denoted  
• in mouse - increased uptake in the lungs, no uptake in the spleen and significant presence in the kidneys and bladder [95] |  |
| $[^{109}\text{Zr}]$DBN | • $6 \times 10^6$ of mouse-derived melanoma cells (mMCS) or mouse derived DCs or human MSCs + 6 MBq in volume of 100 mCi solution [45]  
• $6 \times 10^6$ human cardiopoietic stem cells (CPS) + 6 MBq in volume of 100 mCi solution [45]  
• $5 \times 10^5$ Jurkat/CAR-T cells + 185 kBq/100 mCi (500 mCi in total) [142] | • the effects of intravenously administered radiotracer have not been described yet - however, during our own study, sudden death of BALB/c mice was observed after intravenous administration - the detailed studies on the toxicity of this tracer is required  
• the biodistribution of pure radiotracer has not been described yet – the studies on the pharmacokinetics of this tracer is required |  |
| $[^{124}\text{I}]$HT-(PisS)$_2$Mal | • Jurkat cells; (~100 KBg/10$^6$ cells) [46] | • no adverse effects on animals or patients have been denoted  
• mainly liver and kidneys [264]  
• accumulates mainly in the liver, kidney, but also intestine, lungs, heart, spleen, muscle, pancreas, and brain [265] |  |
| endocytosis |  |  |  |
| $[^{64}\text{Cu}]$PEI | • U937MG cells (1 x 10$^7$) were incubated with 18.5 MBq of $[^{64}\text{Cu}]$PEI; the labeling efficiency was low (20.5%) and the efflux reached over 60% in 27 h [35] | • no adverse effects on cells, animals, or patients have been denoted  
• accumulates in kidneys [266]  
• after I.V. injection to mice, it was found to be located primarily in tissue resident-macrophages; pharmacokinetics depends on the size of Ns; in mouse, after I.V. injection, the total activity of 13 nm Ns was 22 ± 3% in liver, 19 ± 2% in circulating cells and 2 ± 0.1% in spleen, and the remainder was distributed in other organs, including high uptake in lymph nodes [216] |  |
| $[^{89}\text{Zr}]$chitosan | • blood-derived leukocyte fraction; specific radiactivity of 24.7 MBq/mg chitosan nanoparticle [144] | • no adverse effects on animals or patients have been denoted  
• accumulates in kidneys [266] |  |
| $[^{89}\text{Zr}]$dextran Ns | • the cell labeling procedure resulted in the proportion of 15 $\mu$Ci of activity per 8 $\times 10^6$ murine B cells [145] and 11.2 ± 3.25 MBq per 8.4 ± 2.4 $\times 10^6$ murine T cells [147] | • no adverse effects have been denoted  
• after I.V. injection to mice, it was found to be located primarily in tissue resident-macrophages; pharmacokinetics depends on the size of Ns; in mouse, after I.V. injection, the total activity of 13 nm Ns was 22 ± 3% in liver, 19 ± 2% in circulating cells and 2 ± 0.1% in spleen, and the remainder was distributed in other organs, including high uptake in lymph nodes [216] |  |
| $[^{68}\text{Ga}]$MSNs | • 100 (one hundred) MDA-MB-231 breast cancer cells + 323 Bg $[^{68}\text{Ga}]$-MSN [152] | • no adverse effects on animals or patients have been denoted  
• no data were found regarding $[^{68}\text{Ga}]$ MSNs bioaccumulation |  |
| enzymatic reporter gene |  |  |  |
| $[^{131}\text{I}]$HAU | • intravenous injection (0.01 mCi/animal) via the tail vein [267] | • no toxicity from the diagnostic dose reported  
• clearance through urinary excretion (clearance from blood was completed in 24 h); high radioactivity accumulation observed in kidneys and blood in the early phase (1, 4 h); the low radiotracer uptake in non-target tissue; the high tumour/blood ratios enables tumor imaging [267] |  |
Table 6 (continued)

| Radiotracer | Cell type + radioactivity of dosage (administered in vitro in direct and in vivo in indirect cell labeling) | Safety; reported side effects | Data on systemic distribution; absorption coefficient in normal organs |
|-------------|-------------------------------------------------------------------------------------------------|-------------------------------|-------------------------------------------------------------------|
| **transporter reporter gene** | | | |
| 
| [99mTcO4] | intravenous injection of 340 MBq ± 10% of [99mTcO4] in a man [268] | no clinically detectable pharmacologic effects caused by the administration of the diagnostic dose [268] | clearance through urinary excretion; the highest radiotracer uptake in the thyroid, salivary glands, stomach, and urinary bladder [268] |
| | [124I]FIAU | intravenous injection of 400 MBq (10.8 mCi) of [124I]FIAU in man [269] | no clinically detectable pharmacologic effects caused by the administration of the diagnostic dose | clearance through urinary excretion (~50% of the administered radioactivity appears in the urine within 24 h and 70–90% within 48 h after administration); the tracer accumulates in the liver, salivary glands, nasal mucosa, heart, lungs and bower; high in vivo stability (metabolites that account for <10% of the injected dose are m-iodohippuric acid, m-iodobenzoic acid, and 4-hydroxy-3-iodobenzylguanidine and free radioiodide); accumulation of unbound [124I] in the thyroid occurs only with inadequate blockade; the effective dose ~ 0.013 mSv/MBq [269,270] |
| | [111In]-pentetreotide | intravenous injection of 120 to 220 MBq (3.2–5.9 mCi) of [111In]-pentetreotide in man [271] | no clinically detectable pharmacologic effects caused by the administration of the diagnostic dose | rapid blood clearance: 35% of the administered activity remains in the blood at 10 min and only 1% at 20 h after injection; clearance through urinary excretion: (~50% of the administered activity is in the urine by 6 h and 85% within 24 h; the tracer accumulates in liver, spleen, pituitary, thyroid and kidneys, gall bladder; the organs exposed to the highest doses are the kidneys (0.52 mGy/MBq), urinary bladder wall (0.35 mGy/MBq) and spleen (0.34 mGy/MBq); the effective dose: 0.054 mSv/MBq [271,272] |
| **receptor reporter gene** | | | |
| | [18F]FHBG | intravenous injection of 77.7 MBq (2.1 mCi) of [18F]FIAU in a man [273] | no clinically detectable pharmacologic effects caused by administration | clearance through urinary excretion [274,275] |
| | | intravenous bolus injection of a dose of 74 MBq (2 mCi) of [18F]FIAU [274,275] (to limit radiation exposure of thyroid tissue from the formation of free [18F]iodide from the metabolism of [18F]FIAU, patients were given potassium iodide tablets) | | organs with the highest radiation exposure are kidney, liver, spleen, and urinary bladder (doses to most organs ranged from 0.11 to 0.76 mGy/MBq); the effective dose ~ 0.16 to 0.20 mSv/MBq [274] |
| | | | an exponential washout from the different organs during several hours followed by a late peak (>15 h) in the bladder | | no penetration across the blood–brain barrier (however some accumulation observed within intact glioma tumor, probably due to a compromised BBB) |
| | | | no penetration across the blood–brain barrier | PET radiotracers for indirect labeling of cells expressing: | possible detection of HSV1-tk expressing immune cells within these tumors |
| | | | | | |
| | **enzymatic reporter gene** | | | |
| | [124I]FIAU | intravenous injection of 77.7 MBq (2.1 mCi) of [124I]FIAU in a man [273] | no clinically detectable pharmacologic effects caused by administration [274,275] | clearance through urinary excretion [274,275] |
| | | intravenous injection of 50 MBq (1.3 mCi) of [124I]FIAU in a man [274,275] | | organs with the highest radiation exposure are kidney, liver, spleen, and urinary bladder (doses to most organs ranged from 0.11 to 0.76 mGy/MBq); the effective dose ~ 0.16 to 0.20 mSv/MBq [274] |
| | | (to limit radiation exposure of thyroid tissue from the formation of free [124I]iodide from the metabolism of [124I]FIAU, patients were given potassium iodide tablets) | | no penetration across the blood–brain barrier (however some accumulation observed within intact glioma tumor, probably due to a compromised BBB) |
| | | | | PET radiotracers for indirect labeling of cells expressing: | possible detection of HSV1-tk expressing immune cells within these tumors |
| | | | | | |
| | [111In]-pentetreotide | intravenous injection of 120 to 220 MBq (3.2–5.9 mCi) of [111In]-pentetreotide in man [271] | no clinically detectable pharmacologic effects caused by the administration of the diagnostic dose | rapid blood clearance: 35% of the administered activity remains in the blood at 10 min and only 1% at 20 h after injection; clearance through urinary excretion: (~50% of the administered activity is in the urine by 6 h and 85% within 24 h; the tracer accumulates in liver, spleen, pituitary, thyroid and kidneys, gall bladder; the organs exposed to the highest doses are the kidneys (0.52 mGy/MBq), urinary bladder wall (0.35 mGy/MBq) and spleen (0.34 mGy/MBq); the effective dose: 0.054 mSv/MBq [271,272] |
| | | | | PET radiotracers for indirect labeling of cells expressing: | possible detection of HSV1-tk expressing immune cells within these tumors |
| | | | | | |
| | [18F]FHBG | injection of 70.3–229.4 MBq of [18F]FHBG into a hand vein of a man [230,276] | the phase I study showed the safety of, and lack of toxicity of intravenously injected [18F]FHBG tracer for imaging purposes [276] | rapid blood clearance: 8.42 ± 4.76% of the peak blood activity remained at 30 min following injection; primary routes of clearance are renal and hepatobiliary (high activities observed in the bladder, gut, liver, and kidney → possibly not suitable for imaging HSV1-tk gene expression in the lower abdomen); bladder absorbs the highest radiation dose; rapid clearance from all other tissues → low background signal; high in vivo stability (in the urine, 83% of activity 180 min following administration was stable [18F]FHBG); no penetration across the blood–brain barrier (however some accumulation observed within intact glioma tumors or tumor resection sites, probably due to a compromised BBB) [230] → possible detection of HSV1-tk expressing immune cells within these tumors |
| Radiotracer | Cell type + radioactivity of dosage (administered in vitro in direct and in vivo in indirect cell labeling) | Safety; reported side effects | Data on systemic distribution; absorption coefficient in normal organs |
|------------|----------------------------------------------------------|-------------------------------|-------------------------------------------------|
| [18F]FEAU  | mice injected retro-orbitally with 29.6 MBq (800 μCi) of [18F]FEAU [277] | no safety data in man | both renal and hepatobiliary clearance; high activities observed in large intestine, gallbladder, small intestine and kidney [277] |
| [18F]L-FMAU| bolus intravenous injection of ~56 MBq (1.5 mCi) sterile l-[18F]L-FMAU in man [278] | no safety data in man | biliary excretion of the radiotracer; in man high signals observed in liver, kidneys, gall bladder, bladder, the GI tract and myocardium – the accumulation of the radiotracer in liver and myocardium may compromise its use for PET imaging of therapeutic cells at these sites [278] |
| transporter reporter gene | intravenous injection of [18F]TFB (333–407 MBq) in healthy volunteers [279] | safe and non-toxic probe - no immediate or delayed adverse reactions were observed in volunteers after the radiotracer administration; the estimated absorbed radiation doses are acceptable for clinical imaging purposes [279] | a multi-phasic blood clearance of the radiotracer (two rapid clearance phases during the first 20 min, followed by a slower clearance phase); clearance through urinary excretion; high uptakes observed in thyroid, stomach, salivary glands, and bladder; the highest radiation doses were observed in the thyroid, urinary bladder wall, intestine wall, heart wall, kidneys, liver, pancreas and spleen; high in vivo stability of the radiotracer (minor 18F-labeled metabolites in the blood and urine during 4 h analysis) [279] |
| [124I]MIBG | intravenous administration of 3.07–4.84 MBq of [124I]MIBG via tail vein of athymic mice [280] | safe and non-toxic probe [280] | high uptake in heart and bladder before the 2 h time point; thyroid uptake increases after the 24 h time point, whereas uptake in liver, kidneys, and lungs decreases with time; the highest mean equivalent dose is observed in the thyroid; the estimated mean human-equivalent effective dose 0.25 mSv/MBq [280] |
| [18F]MFBG | intravenous bolus injection of a dose of 148–444 MBq (4–12 mCi) of [18F]MFBG [281] | first-in-human study showed the safety of, and lack of toxicity of intravenously injected [18F]MFBG tracer for imaging purposes (no side effects seen in any patients after [18F]MFBG injection); the estimated absorbed radiation doses are acceptable for clinical imaging purposes [281] | rapid and biexponential blood clearance (mean biologic T1/2 of 18 min for rapid phase and 6 h for slower phase); mono-exponential whole-body clearance, with a mean biologic T1/2 of 1.95 h, enabling early imaging at 1 – 2 h after injection; clearance through urinary excretion (45% of the administered activity in the bladder by 1 h after injection) | high activity in blood, liver, and salivary glands, and mild uptake in kidneys and spleen, that decreases with time; urinary bladder receives the highest radiation dose; the effective dose 0.023 ± 0.012 mSv/MBq [281] |
| receptor reporter gene | intravenous injection of 86.9 ± 16.4 MBq (range, 62–112 MBq) of the radiotracer in man [282] | safe and non-toxic probe - no immediate or delayed adverse reactions were observed in volunteers during the one week follow up after the radiotracer administration; the estimated absorbed radiation doses are acceptable for clinical imaging purposes [283] | clearance through urinary excretion (at 4 h after injection 18.8 ± 1.01 μCi of the injected activity was eliminated in the urine) [283] ~ 0.1 mSv/MBq [284] | the highest uptake at 1, 2, and 3 h after administration observed in spleen, kidneys and liver; the highest absorbed organ doses observed in urinary bladder, followed by spleen, kidneys, adrenals and liver [282] the effective dose from 2.1 [282] to 4.8 mSv [283] from 100 MBq injected activity
to track a single cell after i.v. injection. It was shown that a proper radiotracer uptake in brain; the effective radiation dose observed in kidneys (0.0945 mGy/MBq), followed by urinary bladder wall (0.0864 mGy/MBq), submandibular glands (0.0387 mGy/MBq), and liver (0.0380 mGy/MBq); no radiotracer uptake in brain; the effective radiation dose of 370 MBq (10 mCi) [285].

Despite the above-mentioned hurdles, nuclear imaging-based in vivo tracking of immune cells is a valuable technique that may help us to understand the immune system and contribute to the development of therapeutic strategies. However, the room for improvement, besides the current biological and physical limits of the PET scanners, is the limited resolution of the tracers used, which can lead to inaccurate measurements of cell distribution. The use of radiotracers allows for the tracking of immune cells, but their selection is crucial to ensure the safety and accuracy of the results. The use of proper radiotracers, such as [18F]DCFPyL, can provide valuable insights into the behavior of immune cells in vivo.

Table 6 (continued)

| Radiotracer | Cell type + radioactivity of dosage (administered in vivo in direct and in vitro in indirect cell labeling) | Safety; reported side effects | Data on systemic distribution; absorption coefficient in normal organs |
|-------------|-------------------------------------------------------------------------------------------------|-------------------------------|---------------------------------------------------------------|
| [18F]DCFPyL | intravenous administration of 3.6 ± 0.18 MBq/Kg of [18F]DCFPyL [284] | - safe and non-toxic probe - no immediate or delayed adverse reactions were observed in volunteers after the radiotracer administration [285] | - rapid blood clearance [285] |

distribution, activation, proliferation, and survival. Although indirect labeling of immune cells for reporter gene-based tracking in the clinical settings may be considered for adoptive cell therapies, such as CAR-T cells, that are already genetically modified, the genetic modification of primary immune cells for in vivo tracking purposes in humans probably will not be routinely used in the clinical practice. Limited use of reporter genes in man is caused by the fact that genetic modification of the target cell genome with viruses can lead to harmful effects owing to uncontrolled insertional mutagenesis. Genome editing methods, allowing for the reporter gene integration to precise genomic loci, may potentially circumvent this limitation and increase the safety of reporter gene imaging. Currently, available cell labeling techniques do not meet all expectations as they all have advantages and disadvantages. Key issues concerning the fate and distribution of labeled cells to unwanted sites in the body and consequent accumulation of radioactivity or undesirable leakage of radiotracer due to tracked cell premature degradation or simple biochemical degradation of the chelator molecule must be addressed. Consequently, a suitable strategy for immune cell labeling needs to be chosen for each experimental setup. Despite the above-mentioned hurdles, nuclear imaging-based in vivo tracking of immune cells is a valuable technique that may provide us with a noninvasive way of studying the functioning of the immune system and contribute to the development of therapies using or targeting immune cells.

The room for improvement, besides the current biological and physical limits of the PET scanners, are proper approaches for data acquisition and algorithms for data analysis. The recent interesting study [152] showed that a very short acquisition timeframe and a reconstruction algorithm used for tracking single-cell radioactivity required a limited number of photon-coincidence detections and a spline method to track the cell. Importantly, the authors were able to track a single cell after i.v. injection. It was shown that a proper algorithm for a digital PET scanner with sensitive and excellent time-of-flight properties would limit the necessary radioactivity of the cell for its localization [286]. The cell tracking study utilizing PET, recently conducted by Sato et al. on the rhesus monkeys, was fully successful and importantly, no side effects were observed. That would give a potential clinical translation of this excellent preclinical method [135].

However, before the widespread implementation of cell tracking methods in clinical practice will be possible, this method needs to face many regulatory and practical issues. The most important issues to solve seems to be the selection of the proper radiotopes, genetic engineering of the cells, tailoring of cell-labeling methods to particular disease and site, as well as validation of the safety of such approaches.

Funding sources

This paper and research cited in this article are founded by the European Research Council Starting Grant McHAP: 715048 (MK). The contribution of Łukasz Cheda was realized within Project No POWR.03.02.00-00-1009/17-00 (Operational Project Knowledge Education Development 2014-2020 co-financed by European Social Fund) (ŁCh) and the National Science Centre, PRELUDIUM 18 Grant: contract no. UMO-2019/35/N/ST4/01987 (ŁCh). The research described in this paper has been founded by the NCN SONATA BIS: UMO-2015/18/E/N26/00642 grant given to MK from the National Science Centre (Poland).

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We would like to kindly acknowledge Dr. Marta Kiraga from Institute of Civil Engineering, Department of Hydrotechnics, Technology and Management. Warsaw University of Life Sciences, and Msc. Dariusz Zielonka from Institute of Biology, Department of Biochemistry and Microbiology, Warsaw University of Life Sciences, for technical support in the creation of figures. We are grateful to Dr. Elisabetta Manuiali and Dr. Silvia Pavone from Istituto Zooprofilattico Sperimentale dell’Umbria e delle Marche, Italy, for the histopathological examination of murine organ samples.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ccr.2021.214008.

References

[1] M.W. Rohaan, S. Wilgenhof, J.B.A.G. Haanen, Adoptive cellular therapies: the current landscape, Virchows Arch. 474 (2019) 449–461, https://doi.org/10.1007/s00428-018-2484-0.
Intracoronary Injection of 18F-DG-Labelled Progenitor Cell Therapy for Acute Myocardial Infarction, J. Nucl. Med. 48 (2007) 1708–1714, https://doi.org/10.2967/jnumed.106.036238.

D. Pellegrino, A.A. Bousquet, S.C. Dragostakes, J.I. Putnam, G. Mariani, E.A. Carter, Inflammation and Infection: Imaging Properties of 18F-DG-Labelled White Blood Cells Versus, J. Nucl. Med. 46 (2005) 1522–30. PMID: 16692044.

L.A. Forstrom, B.P. Mullan, J.C. Hung, V.J. Lowe, L.M. Thorson, 18F-DG labelling of human leucocytes, Nucl. Med. Commun. 4 (2000) 691–694, https://doi.org/10.1093/nucmedcom/4.10.691.

B. Do, Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-18Ffluoro-D-glucose labelled white blood cells, Mol. Imaging. Biol. 5 (2003) 271–277, https://doi.org/10.1016/S1536-1632(03)00103-3.

S. Yilmaz, A. Aliyer, T. Finkel, T. M. Chin, P. Ballinger, G. 89Zr-Oxine, J Nucl Med.
